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Preamble
Guidelines and Expert Consensus documents aim to present
all the relevant evidence on a particular issue in order
to help physicians to weigh the beneﬁts and risks of a
particular diagnostic or therapeutic procedure. They
should be helpful in everyday clinical decision-making.
A great number of Guidelines and Expert Consensus
Documents have been issued in recent years by the
European Society of Cardiology (ESC) and by different
organizations and other related societies. This profusion
can put at stake the authority and validity of guidelines,
which can only be guaranteed if they have been devel-
oped by an unquestionable decision-making process.
This is one of the reasons why the ESC and others have
issued recommendations for formulating and issuing
Guidelines and Expert Consensus Documents.
In spite of the fact that standards for issuing good
quality Guidelines and Expert Consensus Documents are
well deﬁned, recent surveys of Guidelines and Expert
Consensus Documents published in peer-reviewed jour-
nals between 1985 and 1998 have shown that methodo-
logical standards were not complied with in the vast
majority of cases. It is therefore of great importance
that guidelines and recommendations are presented
in formats that are easily interpreted. Subsequently,
their implementation programmes must also be well
conducted. Attempts have been made to determine
whether guidelines improve the quality of clinical prac-
tice and the utilization of health resources.
The ESC Committee for Practice Guidelines (CPG)
supervises and coordinates the preparation of new Guide-
lines and Expert Consensus Documents produced by Task
Forces, expert groups or consensus panels. The chosen
experts in these writing panels are asked to provide dis-
closure statements of all relationships they may have
which might be perceived as real or potential conﬂicts
of interest. These disclosure forms are kept on ﬁle at
the European Heart House, headquarters of the ESC.
The Committee is also responsible for the endorsement
of these Guidelines and Expert Consensus Documents or
statements.
The Task Force has classiﬁed and ranked the usefulness
or efﬁcacy of the recommended procedure and/or treat-
ments and the Level of Evidence as indicated in the
tables below:
1. Introduction
The aim of these guidelines is to describe the rationale
behind the diagnosis and treatment of acute heart
failure (AHF) in the adult population.
Classes of Recommendations
Class I Evidence and/or general agreement that a given
diagnostic procedure/treatment is beneﬁcial,
useful and effective;
Class II Conﬂicting evidence and/or a divergence of
opinion about the usefulness/efﬁcacy of the
treatment;
Class IIa Weight of evidence/opinion is in favour of use-
fulness/efﬁcacy;
Class IIb Usefulness/efﬁcacy is less well established by
evidence/opinion;
Class III Evidence or general agreement that the treat-
ment is not useful/effective and in some cases
may be harmful.
Use of Class III is discouraged by the ESC.
Levels of Evidence
Level of Evidence A Data derived from multiple random-
ized clinical trials or meta-analyses
Level of Evidence B Data derived from a single random-
ized clinical trial or large non-
randomized studies
Level of Evidence C Consensus of opinion of the experts
and/or small studies; retrospective
studies and registries
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The Committee for Practice Guidelines (CPG) of the
European Society of Cardiology nominated the Task
Force for the AHF Guidelines. The Task Force included
representatives from the Heart Failure Association of
the ESC and members of the European Society of
Intensive Care Medicine (ESICM). The Task Force recom-
mendations were circulated among a review board and
approved by the CPG of the ESC and by the ESICM.
Together with the Guidelines for the diagnosis and treat-
ment of chronic heart failure1 these Guidelines form the
recommendations on diagnosis and treatment of heart
failure.
The recommendations are also published as an un-
abridged version of the document,2 as a pocket guideline,
and as an ESC educational product CD.
2. Epidemiology, aetiology, and
clinical context
The combination of the aging of the population in many
countries, and improved survival after acute myocardial
infarction (AMI)3 has created a rapid growth in the
number of patients currently living with chronic heart
failure (CHF),4 with a concomitant increase in the
number of hospitalizations for decompensated heart
failure. Coronary heart disease is the aetiology of AHF
in 60–70% of patients,5–7 particularly in the elderly popu-
lation. In younger subjects, AHF is frequently caused by
dilated cadiomyopathy, arrhythmia, congenital or valvu-
lar heart disease, or myocarditis. The causes and compli-
cations of AHF are described in Table 1.
The management of heart failure consumes 1–2% of
health care expenditure in European countries,8,9 with
around 75% relating to inpatient care. Advanced heart
failure and related acute decompensation have become
the single most costly medical syndrome in
cardiology.10,11
Patients with AHF have a very poor prognosis. Mortality
is particularly high in patients with acute myocardial
infarction (AMI) accompanied by severe heart failure,
with a 30% 12 month mortality.12 Likewise, in acute
pulmonary oedema a 12% in-hospital and 40% 1 year
mortality have been reported.13
About 45% of patients hospitalized with AHF will be
rehospitalized at least once (and 15% at least twice)
within twelve months.14,15 Estimates of the risk of
death or rehospitalization within 60 days of admission
vary from 30 to 60%, depending on the population
studied.5,6,16–19
I. Deﬁnitions, diagnostic steps,
instrumentation and monitoring
of the patient with AHF
3. Deﬁnition and clinical classiﬁcation of AHF
3.1. Deﬁnition
Acute heart failure is deﬁned as the rapid onset of symp-
toms and signs secondary to abnormal cardiac function. It
may occur with or without previous cardiac disease. The
cardiac dysfunction can be related to systolic or diastolic
dysfunction, to abnormalities in cardiac rhythm, or to
pre-load and after-load mismatch. It is often life threa-
tening and requires urgent treatment.
AHF can present itself as acute de novo (new onset of
acute heart failure in a patient without previously
known cardiac dysfunction) or acute decompensation of
chronic heart failure.
The patient with acute heart failure may present with
one of several distinct clinical conditions (Table 2 ):
(i) Acute decompensated heart failure (de novo or
as decompensation of chronic heart failure) with
signs and symptoms of acute heart failure, which
are mild and do not fulﬁl criteria for cardiogenic
shock, pulmonary oedema or hypertensive crisis.
(ii) Hypertensive AHF: Signs and symptoms of heart
failure are accompanied by high blood pressure
and relatively preserved left ventricular function
with a chest radiograph compatible with acute
pulmonary oedema.
Table 1 Causes and precipitating factors in AHF
(1) Decompensation of pre-existing chronic heart failure
(e.g. cardiomyopathy)
(2) Acute coronary syndromes
(a) myocardial infarction/unstable angina with large
extent of ischaemia and ischaemic dysfunction
(b) mechanical complication of acute myocardial
infarction
(c) right ventricular infarction
(3) Hypertensive crisis
(4) Acute arrhythmia (ventricular tachycardia, ventricular
ﬁbrillation, atrial ﬁbrillation or ﬂutter, other supraven-
tricular tachycardia)
(5) Valvular regurgitation (endocarditis, rupture of chordae
tendinae, worsening of pre-existing valvular
regurgitation)
(6) Severe aortic valve stenosis
(7) Acute severe myocarditis
(8) Cardiac tamponade
(9) Aortic dissection
(10) Post-partum cardiomyopathy
(11) Non-cardiovascular precipitating factors
(a) lack of compliance with medical treatment
(b) volume overload
(c) infections, particularly pneumonia or
septicaemia
(d) severe brain insult
(e) after major surgery
(f) reduction in renal function
(g) asthma
(h) drug abuse
(i) alcohol abuse
(j) phaeochromocytoma
(12) High output syndromes
(a) septicaemia
(b) thyrotoxicosis crisis
(c) anaemia
(d) shunt syndromes
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(iii) Pulmonary oedema (veriﬁed by chest X-ray) accom-
panied by severe respiratory distress, with crackles
over the lung and orthopnoea, with O2 saturation
usually ,90% on room air prior to treatment.
(iv) Cardiogenic shock: Cardiogenic shock is deﬁned as
evidence of tissue hypoperfusion induced by heart
failure after correction of pre-load. There is no
clear deﬁnition for haemodynamic parameters,
which explains the differences in prevalence and
outcome reported in studies (Table 2 ), but cardio-
genic shock is usually characterized by reduced
blood pressure (systolic BP ,90 mmHg or a drop of
mean arterial pressure . 30 mmHg) and/or low
urine output (,0.5 ml/kg/h), with a pulse rate
.60 b.p.m. with or without evidence of organ con-
gestion. There is a continuum from low cardiac
output syndrome to cardiogenic shock.
(v) High output failure is characterized by high cardiac
output, usually with high heart rate (caused by
arrhythmias, thyrotoxicosis, anaemia, Paget’s
disease, iatrogenic or by other mechanisms), with
warm peripheries, pulmonary congestion, and some-
times with low BP as in septic shock.
(vi) Right heart failure is characterized by low output
syndrome with increased jugular venous pressure,
increased liver size and hypotension.
Various other classiﬁcations of the acute heart failure
syndrome are utilized in coronary care and intensive
care units. The Killip classiﬁcation is based on clinical
signs and chest X-ray ﬁndings, and the Forrester classiﬁ-
cation is based on clinical signs and haemodynamic
characteristics. These classiﬁcations have been validated
in acute heart failure after AMI and thus are best
applied to acute de novo heart failure. The third ‘clinical
severity’ classiﬁcation has been validated in a cardiomyo-
pathy service20 and is based on clinical ﬁndings.21 It is most
applicable to chronic decompensated heart failure.22
3.1.1. Killip classiﬁcation. The Killip classiﬁcation was
designed to provide a clinical estimate of the severity
of myocardial derangement in the treatment of AMI:23
Stage I—No heart failure. No clinical signs of cardiac
decompensation;
Stage II—Heart failure. Diagnostic criteria include rales,
S3 gallop and pulmonary venous hypertension.
Pulmonary congestion with wet rales in the
lower half of the lung ﬁelds;
Stage III—Severe heart failure. Frank pulmonary oedema
with rales throughout the lung ﬁelds;
Stage IV—Cardiogenic shock. Signs include hypotension
(SBP  90mmHg), and evidence of peripheral
vasoconstriction such as oliguria, cyanosis and
diaphoresis.
3.1.2. Forrester classiﬁcation. The Forrester AHF
classiﬁcation was also developed in AMI patients, and
describes four groups according to clinical and haemo-
dynamic status24 (Figure 1 ). Patients are classiﬁed
clinically on the basis of peripheral hypoperfusion
(ﬁlliform pulse, cold clammy skin, peripheral cyanosis,
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hypotension, tachycardia, confusion, oliguria) and pul-
monary congestion (rales, abnormal chest X-ray), and
haemodynamically on the basis of a depressed cardiac
index (2.2 L/min/m2) and elevated pulmonary capillary
pressure (.18 mmHg). The original paper deﬁned the
treatment strategy according to the clinical and haemo-
dynamic status. Mortality was 2.2% in group I, 10.1% in
group II, 22.4% in group III, and 55.5% in group IV.
3.1.3. ‘Clinical severity’ classiﬁcation. The clinical
severity classiﬁcation is based on observation of the
peripheral circulation (perfusion) and on auscultation of
the lungs (congestion). The patients can be classiﬁed as
Class I (Group A) (warm and dry), Class II (Group B)
(warm and wet), Class III (Group L) (cold and dry), and
Class IV (Group C) (cold and wet). This classiﬁcation has
been validated prognostically in a cardiomyopathy
service,20 and is therefore applicable to patients
with chronic heart failure, whether hospitalized or
outpatients.
3.2. The clinical syndrome of AHF
AHF is a clinical syndrome, with reduced cardiac output,
tissue hypoperfusion, increase in the pulmonary capillary
wedge pressure (PCWP), and tissue congestion. The
underlying mechanism may be cardiac or extra-cardiac,
and may be transient and reversible with resolution of
the acute syndrome, or may induce permanent damage
leading to chronic heart failure. The cardiac dysfunc-
tion can be related to systolic or diastolic myocardial
dysfunction (mainly induced by ischaemia or infection),
acute valvular dysfunction, pericardial tamponade,
abnormalities of cardiac rhythm, or pre-load/after-load
mismatch. Multiple extra-cardiac pathologies may result
in acute heart failure by changing the cardiac loading
conditions for example (i) increased after-load due
to systemic or pulmonary hypertension or massive
pulmonary emboli, (ii) increased pre-load due to
increased volume intake or reduced excretion due to
renal failure or endocrinopathy, or (iii) high output
state due to infection, thyrotoxicosis, anaemia, Paget’s
disease. Heart failure can be complicated by co-existing
end-organ disease. Severe heart failure can also induce
multi-organ failure, which may be lethal.
Appropriate long-term medical therapy and, if pos-
sible, anatomical correction of the underlying patho-
logy may prevent further AHF syndrome ‘attacks’ and
improve the poor long-term prognosis associated with
this syndrome.
The clinical AHF syndrome may be classiﬁed as predo-
minantly left or right forward failure, left or right back-
ward failure, or a combination of these.
3.2.1. Forward (left and right) AHF. Forward acute
heart failure may be mild-to-moderate with only effort
fatigue, up to severe with manifestations of reduced
tissue perfusion at rest with weakness, confusion, drowsi-
ness, paleness with peripheral cyanosis, cold clammy
skin, low blood pressure, ﬁlliform pulse, and oliguria, cul-
minating in the full blown presentation of cardiogenic
shock.
This syndrome may be induced by a large variety of
pathologies. An adequate history may indicate the main
diagnosis for example (i) acute coronary syndrome with
the relevant risk factors, past history, and suggestive
symptoms; (ii) acute myocarditis with a recent history
suggestive of acute viral infection; (iii) acute valvular
dysfunction with a history of chronic valve disease or
valve surgery, infection with the possibility of bacterial
endocarditis, or chest trauma; (iv) pulmonary embolism
with a relevant history and suggestive symptoms; or
(v) pericardial tamponade.
Figure 1 Clinical classiﬁcation of the mode of heart failure (Forrester classiﬁcation). H I-IV refers to haemodynamic severity, with reference ﬁgures for
CI and pulmonary capillary pressures shown on the vertical and horizontal axes, respectively. C I-IV refers to clinical severity.
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Physical examination of the cardiovascular system may
be indicative of the main diagnosis, for example by dis-
tended neck veins and paradoxical pulse (pericardial
tamponade), mufﬂed heart sounds related to myocardial
systolic dysfunction, or the disappearance of artiﬁcial
valve sounds or an appropriate murmur indicating a valv-
ular problem.
In forward AHF immediate management should include
supportive treatment to improve cardiac output and
tissue oxygenation. This can be achieved with vasodilat-
ing agents, ﬂuid replacement to achieve an optimal
pre-load, short-term inotropic support and (sometimes)
intra-aortic balloon counterpulsation.
3.2.2. Left-heart backward failure. Left-heart back-
ward failure may be related to left ventricular
dysfunction with varying degrees of severity, from mild-
to-moderate with only exertional dyspnoea, to pulmonary
oedema presenting with shortness of breath (dry cough,
sometimes with frothy sputum), pallor or even cyanosis,
cold clammy skin, and normal or elevated blood pressure.
Fine rales are usually audible over the lung ﬁelds. Chest
X-ray shows pulmonary congestion/oedema.
Pathology of the left heart may be responsible for this
syndrome, including: myocardial dysfunction related to
chronic existing conditions; acute insult such as myocar-
dial ischaemia or infarction; aortic and mitral valve dys-
function; cardiac rhythm disturbances; or tumours of the
left heart. Extra-cardiac pathologies may include severe
hypertension, high output states (anaemia, thyrotoxi-
cosis) and neurogenic states (brain tumours or trauma).
Physical examination of the cardiovascular system,
including the apex beat, the quality of the heart sounds,
the presence of murmurs, and auscultation of the
lungs for ﬁne rales and expiratory wheezing (‘cardiac
asthma’) may be indicative of the main diagnosis.
In left heart backward failure patients should be
treated mainly with vasodilation and the addition of
diuretics, bronchodilators and narcotics, as required.
Respiratory support may be necessary. This can either
be with continuous positive airway pressure (CPAP) or
non-invasive positive pressure ventilation, or in some
circumstances invasive ventilation may be required
following endotracheal intubation.
3.2.3. Right-heart backward failure. The syndrome of
acute right heart failure is related to pulmonary and
right heart dysfunction, including exacerbations of
chronic lung disease with pulmonary hypertension, or
acute massive lung disease (e.g. massive pneumonia or
pulmonary embolism), acute right ventricular infarction,
tricuspid valve malfunction (traumatic or infectious), and
acute or sub-acute pericardial disease. Advanced left
heart disease progressing to right-sided failure should
also be considered, and similarly long-standing congeni-
tal heart disease with evolving right ventricular failure
should be taken into account. Non-cardiopulmonary
pathologies include nephritic/nephrotic syndrome and
end-stage liver disease. Various vasoactive peptide-
secreting tumours should also be considered.
The typical presentation is with fatigue, pitting ankle
oedema, tenderness in the upper abdomen (due to liver
congestion), shortness of breath (with pleural effusion)
and distension of the abdomen (with ascites). The
full-blown syndrome includes anasarca with liver dysfunc-
tion and oliguria.
History and physical examination should conﬁrm the
syndrome of acute right heart failure, indicate the sus-
pected diagnosis and guide further investigation, which
is likely to include ECG, blood gases, D-dimer, chest
X-ray, cardiac Doppler-echocardiography, angiography
or chest CT scan.
In right heart backward failure ﬂuid overload is
managed with diuretics, including spironolactone, and
sometimes with a short course of low dose (‘diuretic
dose’) of dopamine. Concomitant treatment may
include: antibiotics for pulmonary infection and bacterial
endocarditis; Caþþ channel blockers, nitric oxide, or
prostaglandins for primary pulmonary hypertension; and
anticoagulants, thrombolytics, or thrombectomy for
acute pulmonary embolism.
4. Pathophysiology of AHF
4.1. The vicious circle in the acute failing heart
The ﬁnal common denominator in the syndrome of AHF
is a critical inability of the myocardium to maintain
a cardiac output sufﬁcient to meet the demands of the
peripheral circulation. Irrespective of the underlying
cause of AHF, a vicious circle is activated that, if not
appropriately treated, leads to chronic heart failure
and death. This is shown in Figure 2, and is described
in detail elsewhere.2
In order for patients with AHF to respond to treatment
the myocardial dysfunction must be reversible. This is
particularly important in AHF due to ischaemia, stunning
or hibernation, where a dysfunctional myocardium can
return to normal when appropriately treated.
4.2. Myocardial stunning
Myocardial stunning is the myocardial dysfunction that
occurs following prolonged ischaemia, which may persist
in the short-term even when normal blood ﬂow is
restored.25,26 The intensity and duration of stunning is
dependent on the severity and duration of the preceding
ischaemic insult.26
4.3. Hibernation
Hibernation is deﬁned as an impairment of myocardial
function due to severely reduced coronary blood ﬂow
although myocardial cells are still intact. By improving
blood ﬂow and oxygenation, hibernating myocardium
can restore its normal function.27
Hibernating myocardium and stunning can co-exist.
Hibernation improves in time with reinstitution of blood
ﬂow and oxygenation, whilst stunned myocardium
retains inotropic reserve and can respond to inotropic
stimulation.26,28 Since these mechanisms depend on the
duration of myocardial damage, a rapid restoration of
oxygenation and blood ﬂow is mandatory to reverse
these pathophysiological alterations.
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5. Diagnosis of AHF
The diagnosis of AHF is based on the symptoms and
clinical ﬁndings, supported by appropriate investiga-
tions such as ECG, chest X-ray, biomarkers, and Doppler-
echocardiography (Figure 3 ). The patient should be
classiﬁed according to previously described criteria for
systolic and/or diastolic dysfunction (Figure 4 ), and by
the characteristics of forward or backward left or right
heart failure.
5.1. Clinical evaluation
Systematic clinical assessment of the peripheral circula-
tion, venous ﬁlling, and peripheral temperature are
important.
Right ventricular (RV) ﬁlling in decompensated heart
failure may usually be evaluated from the central jugular
venous pressure. When the internal jugular veins are
impractical for evaluation (e.g. due to venous valves) the
external jugular veins can be used. Caution is necessary
in the interpretation of high measured central venous
pressure (CVP) in AHF, as this may be a reﬂection of
decreased venous compliance together with decreased
RV compliance even in the presence of low RV ﬁlling.
Figure 3 Diagnosis of AHF.
Figure 4 Assessment of LV function in AHF.
Figure 2 Pathophysiology of the syndrome of acute heart failure. Following acute critical events, LV deterioration occurs rapidly and requires urgent
medical treatment. The pathophysiology of the syndrome of heart failure is summarized. Mechanical, haemodynamic and neurohormonal changes are
similar but not identical to those observed in CHF. The time course of development or reversal of these changes varies considerably and strongly
depends on the underlying cause of LV deterioration as well as pre-existing cardiovascular disease. However, changes develop rapidly and therefore
AHF is considerably different to the syndrome of CHF.
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Left sided ﬁlling pressure is assessed by chest ausculta-
tion, with the presence of wet rales in the lung ﬁelds
usually indicating raised pressure. The conﬁrmation,
classiﬁcation of severity, and clinical follow-up of pul-
monary congestion and pleural effusions should be done
using the chest X-ray.
Class I recommendation, level of evidence C
Again, in acute conditions the clinical evaluation of
left-sided ﬁlling pressure may be misleading due to the
rapidly evolving clinical situation. Cardiac palpation and
auscultation for ventricular and atrial gallop rhythms
(S3, S4) should be performed. The quality of the heart
sounds, and the presence of atrial and ventricular
gallops and valvular murmurs are important for diagnosis
and clinical assessment. Assessment of the extent of
arteriosclerosis by detecting missing pulses and the pre-
sence of carotid and abdominal bruits is often important,
particularly in elderly subjects.
5.2. Electrocardiogram (ECG)
A normal ECG is uncommon in acute heart failure. The
ECG is able to identify the rhythm, and may help deter-
mine the aetiology of AHF and assess the loading con-
ditions of the heart. It is essential in the assessment
of acute coronary syndromes.29–31 The ECG may also
indicate acute right or left ventricular or atrial strain,
perimyocarditis and pre-existing conditions such as left
and right ventricular hypertrophy or dilated cardiomyo-
pathy. Cardiac arrhythmia should be assessed in the
12-lead ECG as well as in continuous ECG monitoring.
5.3. Chest X-ray and imaging techniques
Chest X-ray and other imaging should be performed early
for all patients with AHF to evaluate pre-existing chest or
cardiac conditions (cardiac size and shape) and to assess
pulmonary congestion. It is used both for conﬁrmation of
the diagnosis, and for follow-up of improvement or unsa-
tisfactory response to therapy. Chest X-ray allows the
differential diagnosis of left heart failure from inﬂamma-
tory or infectious lung diseases. Chest CT scan with or
without contrast angiography and scintigraphy may be
used to clarify the pulmonary pathology and diagnose
major pulmonary embolism. CT scan or transesophageal
echocardiography should be used in cases of suspicion
of aortic dissection.
5.4. Laboratory tests
A number of laboratory tests should be performed in AHF
patients (Table 3 ). Arterial blood gas analysis (Astrup)
enables assessment of oxygenation (pO2), respiratory
adequacy (pCO2), acid–base balance (pH), and base
deﬁcit, and should be performed in all patients with
severe heart failure. Non-invasive measurement with
pulse oximetry and end-tidal CO2 can often replace
Astrup (Level of evidence C) but not in very low
output, vasocontricted shock states. Measurement of
venous O2 saturation (i.e. in the jugular vein) may be
useful for an estimation of the total body oxygen
supply-demand balance.
Plasma B-type natriuretic peptide (BNP) is released
from the cardiac ventricles in response to increased
wall stretch and volume overload and has been used to
exclude and/or identify congestive heart failure (CHF)
in patients admitted, for dyspnoea, to the emergency
department.1,32 Decision cut points of 300 pg/mL for
NT-proBNP and 100 pg/mL for BNP have been proposed,
but the older population has been poorly studied.
During ‘ﬂash’ pulmonary oedema, BNP levels may
remain normal at the time of admission. Otherwise,
BNP has a good negative predictive value to exclude
heart failure.33 Various clinical conditions may affect
the BNP concentration including renal failure and septi-
caemia. If elevated concentrations are present, further
diagnostic tests are required. If AHF is conﬁrmed,
increased levels of plasma BNP and NT-pro BNP carry
important prognostic information. The exact role of
BNP remains to be fully clariﬁed.34
5.5. Echocardiography
Echocardiography is an essential tool for the evaluation
of the functional and structural changes underlying or
associated with AHF, as well as in the assessment of
acute coronary syndromes.
Class I recommendation, level of evidence C
Echocardiography with Doppler imaging should be used
to evaluate and monitor regional and global left and right
ventricular function, valvular structure and function,
possible pericardial pathology, mechanical complications
of acute myocardial infarction and—on rare occasions—
space occupying lesions. Cardiac output can be estimated
by appropriate Doppler aortic or pulmonary time velocity
contour measurements. An appropriate echo-Doppler
study can also estimate pulmonary artery pressures
(from the tricuspid regurgitation jet) and has also
Table 3 Laboratory tests in patients hospitalized with AHF
Blood count Always
Platelet count Always
INR If patient anticoagulated or in
severe heart failure
CRP Always
D-dimer Always (may be falsely positive
if CRP elevated or patient
has been hospitalized for
prolonged period)
Urea and Electrolytes
(Naþ, Kþ, Urea,
Creatinine)
Always
Blood glucose Always
CKMB, cardiac TnI/TnT Always
Arterial blood gases In severe heart failure, or
in diabetic patients
Transaminases To be considered
Urinanalysis To be considered
Plasma BNP or NTproBNP To be considered
Other speciﬁc laboratory tests should be taken for differential
diagnostic purposes or in order to identify end-organ dysfunction.
INR ¼ international normalized ratio of thromboplastin time; TnI ¼
troponin I; TnT ¼ troponin T.
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been used for the monitoring of left ventricular
pre-load.35–37 Echocardiography has not been validated
with right heart catheterization in patients with AHF.38
5.6. Other investigations
In cases of coronary-artery-related complications such
as unstable angina or myocardial infarction, angiography
is important and angiography-based revascularization
therapy has been shown to improve prognosis.29,30
Class I recommendation, level of evidence B
Coronary arteriography is also often indicated in pro-
longed AHF, unexplained by other investigations, as
recommended in the guidelines for diagnosis of CHF.1
Insertion of a pulmonary artery catheter (PAC) may
assist in making the diagnosis of AHF. See Section 7.2.3
for further details.
6. Goals of the treatment of AHF
The immediate goals are to improve symptoms and
to stabilize the haemodynamic condition (Table 4,
Figure 5 ).40–51 An improvement in haemodynamic
parameters only may be misleading, however, and a con-
comitant improvement in symptoms (dyspnoea and/or
fatigue) is generally required.52 These short-term bene-
ﬁts must also be accompanied by favourable effects on
longer-term outcomes. This is likely to be achieved by
avoidance, or limitation, of myocardial damage.
Another objective of treatment is reduction in the
clinical signs of HF. A reduction in body weight, and/or
an increase in diuresis, are beneﬁcial effects of therapy
Figure 5 Immediate goals in treatment of the patients with AHF. In coronary patients mean blood pressure (mBP) should be higher to ensure coronary
perfusion, mBP .70, or systolic .90 mmHg.
Table 4 Goals of treatment of the patient with AHF
Clinical
# symptoms (dyspnoea and/or fatigue)
# clinical signs
# body weight
" diuresis
" oxygenation
Laboratory
Serum electrolyte normalization
# BUN and/or creatinine
# S-bilirubin
# plasma BNP
Blood glucose normalization
Haemodynamic
# pulmonary capillary wedge pressure to ,18 mmHg
" cardiac output and/or stroke volume
Outcome
# length of stay in the intensive care unit
# duration of hospitalization
" time to hospital re-admission
# mortality
Tolerability
Low rate of withdrawal from therapeutic measures
Low incidence of adverse effects
BUN ¼ blood urea nitrogen.
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in congestive and oliguric patients with AHF.44,53 Simi-
larly, an improvement in oxygen saturation, renal and/
or hepatic function, and/or serum electrolytes are mean-
ingful goals of treatment. Plasma BNP concentration can
reﬂect haemodynamic improvement and decreased
levels are beneﬁcial.
Beneﬁcial effects of therapy on outcome include
reductions in the duration of intravenous vasoactive
therapy, the length of stay, and the readmission
rate with an increase in the time to readmission.52,54,55
A reduction in both in-hospital and long-term mortality
is also a major goal of treatment.
Lastly, a favourable safety and tolerability proﬁle is
also necessary for any treatment used in patients with
AHF. Any agent used in this condition should be associ-
ated with a low withdrawal rate with a relatively low
incidence of untoward side effects.
6.1. Organization of the treatment of AHF
Best results are achieved if patients with AHF are treated
promptly by expert staff in areas reserved for heart
failure patients. An experienced cardiologist and/or
other suitably trained staff should treat AHF patients.
The diagnostic services should provide early access to
diagnostic procedures such as echocardiography and
coronary angiography, as needed.
Treatment of patients with AHF requires a treatment
plan in the hospital system.50
Class I recommendation, level of evidence B
Comparative studies have shown shorter hospitaliz-
ation time in patients treated by staff trained in heart
failure management.17 The treatment of AHF should be
followed by a subsequent HF clinic programme when
applicable and as recommended by ESC guidelines.1
The care and information needs of the acutely ill
patient and his/her family will usually be addressed by
expert nurses.
Heart failure staff nurses and cardiology/heart failure/
intensive care specialists should be given the opportunity
for continuing professional education.
Recommendations on the standard structure, nursing
staff and equipment requirements in intensive cardiology
care units and relevant step-down care units based on
the expert opinion of the Working Group of Acute Cardiac
Care are under preparation.
7. Instrumentation and monitoring of
patients in AHF
Monitoring of the patient with AHF should be initiated as
soon as possible after his/her arrival at the emergency
unit, concurrently with ongoing diagnostic measures
addressed at determining the primary aetiology. The
types and level of monitoring required for any individual
patient vary widely depending on the severity of the
cardiac decompensation and the response to initial
therapy. Local logistic issues may also be relevant. The
guidelines on monitoring discussed here are based on
expert opinion.
7.1. Non-invasive monitoring
In all critically ill patients, BP measurements should
be made routinely; blood pressure, temperature,
respiratory rate, heart rate, the electrocardiogram and
blood pressure is mandatory. Some laboratory tests
should be done repeatedly i.e. electrolytes, creatinine
and glucose or markers for infection or other metabolic
disorders. Hypo– or hyperkalaemia must be controlled.
These can all be monitored easily and accurately with
modern automated equipment. If the patient becomes
more unwell, the frequency of these observations will
need to be increased.
ECG monitoring (arrhythmias and ST segment) is
necessary during the acute decompensation phase, par-
ticularly if ischaemia or arrhythmia is responsible for
the acute event.
Class I recommendation, level of evidence C
Maintenance of normal blood pressure is critical during
the initiation of therapy, and consequently it should be
measured regularly (e.g. every 5 minutes), until the
dosage of vasodilators, diuretics or inotropes has been
stabilized. The reliability of non-invasive, automatic
plethysmographic measurement of blood pressure is
good in the absence of intense vasoconstriction and
very high heart rate.
Class I recommendation, level of evidence C
The pulse oximeter is a simple non-invasive device that
estimates the arterial saturation of haemoglobin with
oxygen (SaO2). The estimate of the SaO2 is usually
within 2% of a measured value from a co-oximeter,
unless the patient is in cardiogenic shock. The pulse
oximeter should be used continuously on any unstable
patient who is being treated with a fraction of inspired
oxygen (FiO2) that is greater than in air. It should also
be used at regular intervals (every hour) on any patient
receiving oxygen therapy for an acute decompensation.
Class I recommendation, level of evidence C
Cardiac output and pre-load can be monitored
non-invasively with the use of Doppler techniques (see
Section 5.5.). There is little to no evidence to help
choose which of these to monitor and it makes no differ-
ence as long as the limitations of individual monitor-
ing devices are understood and the data are used
appropriately.
Class IIb recommendation, level of evidence C
7.2. Invasive monitoring
7.2.1. Arterial line. The indications for the insertion of
an in-dwelling arterial catheter are the need for either
continuous beat-to-beat analysis of arterial blood press-
ure due to haemodynamic instability or the requirement
for multiple arterial blood analyses. The complication
rate for the insertion of a 20-gauge 2-inch radial artery
catheter is low.
Class IIb recommendation, level of evidence C
7.2.2. Central venous pressure lines. Central venous
lines provide access to the central venous circulation
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and are therefore useful for the delivery of ﬂuids and
drugs and can also be used to monitor the CVP and
venous oxygen saturation (SvO2) in the superior vena
cava (SVC) or right atrium, which provides an estimate
of oxygen transport.
Class II b recommendation, level of evidence C
Caution has to be advised, however, to avoid the
over-interpretation of right atrial pressure measure-
ments, as these rarely correlate with left atrial pres-
sures, and therefore left ventricular (LV) ﬁlling
pressures, in patients with AHF. CVP measurements are
also affected by the presence of signiﬁcant tricuspid
regurgitation and positive end-expiratory pressure
(PEEP) ventilation.
Class I recommendation, level of evidence C
7.2.3. Pulmonary artery catheter. The pulmonary
artery catheter (PAC) is a balloon ﬂotation catheter
that measures pressures in the superior vena cava
(SVC), right atrium, right ventricle and pulmonary
artery as well as cardiac output. Modern catheters can
measure the cardiac output semi-continuously as well
as the mixed venous oxygen saturation and right ventri-
cular end diastolic volume and ejection fraction.
Although the insertion of a PAC for the diagnosis of AHF
is usually unnecessary, it can be used to distinguish
between a cardiogenic and a non-cardiogenic mechanism
in complex patients with concurrent cardiac and pulmo-
nary disease. The PAC is also frequently used to estimate
PCWP, cardiac output and other haemodynamic variables
and therefore guide therapy in the presence of severe
diffuse pulmonary pathology or ongoing haemodynamic
compromise not resolved by initial therapy.57,58 PCWP
is not an accurate reﬂection of left ventricular end–
diastolic pressure (LVEDP) in patients with mitral stenosis
(MS) aortic regurgitation (AR), ventricular interdepen-
dence, high airway pressure, or stiff LV, due to, for
example, left ventricular hypertrophy (LVH), diabetes,
ﬁbrosis, inotropes, obesity, ischaemia. Severe tricuspid
regurgitation, frequently found in patients with AHF,
can overestimate or underestimate cardiac output
measured by thermodilution.
Several retrospective studies assessing the use of the
PAC in acute myocardial infarction demonstrated
increased mortality with the PAC. These observations
were partially explained by case-mix differences
between the groups of the study.59–61 Similar observa-
tional ﬁndings have subsequently been reported in
other groups of patients.47,61,62 A recent prospective
randomized study enrolling a mixed group of critically ill
patients failed to demonstrate a difference in outcome,
although randomization to the PAC led to increased
ﬂuid resuscitation within the ﬁrst 24 h. The PAC did not
cause harm to patients, rather it was the use of the infor-
mation derived from the catheter (sometimes in an inap-
propriate fashion) that was detrimental.48
The use of a PAC is recommended in haemodynamically
unstable patients who are not responding in a predictable
fashion to traditional treatments, and in patients with
a combination of congestion and hypoperfusion. In
these cases it is inserted in order to ensure optimal
ﬂuid loading of the ventricles and to guide49 vasoactive
therapies and inotropic agents (Table 5 ). Because the
complications increase with the duration of its use, it is
critical to insert the catheter when speciﬁc data are
needed (usually regarding the ﬂuid status of the
patient) and to remove it as soon as it is of no further
help (i.e. when diuretic and vasodilating therapy have
been optimized).
Class IIb recommendation, level of evidence C
In cardiogenic shock and prolonged severe low output
syndrome it is recommended that the mixed venous
oxygen saturation from the pulmonary artery be
measured as an estimation of oxygen extraction
(SpO2–SvO2). The aim should be to maintain SvO2 above
65% in patients with AHF.
II. Treatment of AHF
8. General medical issues in the
treatment of AHF
Infections: Patients with advanced AHF are prone to
infectious complications, commonly respiratory or
Table 5 General therapeutic approach in AHF by ﬁndings on invasive haemodynamic monitoring
Haemodynamic
characteristic
Suggested therapeutic approach
CI Decreased Decreased Decreased Decreased Maintained
PCWP Low High or Normal High High High
SBP mmHg .85 ,85 .85
Outline of
therapy
Fluid loading Vasodilator
(nitroprusside,
NTG) ﬂuid
loading may
become necessary
Consider inotropic
agents
(dobutamine,
dopamine) and
i.v. diuretics
Vasodilators
(nitroprusside,
NTG) and i.v. diuretics
and consider inotrope
(dobutamine,
levosimendan, PDEI)
i.v. diuretics
If SBP is low,
vasoconstrictive
inotropes
In AHF patients: Decreased CI: ,2.2 L/min/m2; PCWP: low if ,14 mmHg, high if .18–20 mmHg.
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urinary tract infections, septicaemia, or nosocomial
infection with Gram positive bacteria. An increase in
C-reactive protein (CRP) and a decrease in general con-
dition may be the only signs of infection—fever may be
absent. Meticulous infection control and measures to
maintain skin integrity are mandatory. Routine cultures
are recommended. Prompt antibiotic therapy should be
given when indicated.
Diabetes: AHF is associated with impaired metabolic
control. Hyperglycaemia occurs commonly. Routine hypo-
glycaemic drugs should be stopped and glycaemic control
should be obtained by using short-acting insulin titrated
according to repeated blood glucose measurements.
Normoglycaemia improves survival in diabetic patients
who are critically ill.50
Catabolic state: negative caloric and nitrogen balance
is a problem in ongoing AHF. This is related to reduced
caloric intake due to reduced intestinal absorption.
Care should be undertaken to maintain calorie and
nitrogen balance. Serum albumin concentration, as well
as nitrogen balance, may help to monitor metabolic
status.
Renal failure: a close interrelationship exists between
AHF and renal failure. Both may cause, aggravate, and
inﬂuence, the outcome of the other. Close monitoring
of renal function is mandatory. Preservation of renal
function is a major consideration in the selection of the
appropriate therapeutic strategy for these patients.
9. Oxygen and ventilatory assistance
9.1. Rationale for using oxygen in AHF
The maintenance of an SaO2 within the normal range
(95–98%) is important in order to maximize oxygen deliv-
ery to the tissues and tissue oxygenation, thus helping
to prevent end-organ dysfunction and multiple organ
failure.
Class I recommendation, level of evidence C
This is best achieved ﬁrst by ensuring that there is a
patent airway and then by administration of an increased
FiO2. Endotracheal intubation is indicated if these
measures fail to improve tissue oxygenation.
Class IIa recommendation, level of evidence C
Despite this intuitive approach to giving oxygen, there
is little to no evidence available that giving increasing
doses of oxygen results in an improved outcome.
Studies have demonstrated that hyperoxia can be associ-
ated with reduced coronary blood ﬂow, reduced cardiac
output, increased blood pressure, increased systemic
vascular resistance, and a trend to higher mortality.51
The administration of increased concentrations of
oxygen to hypoxaemic patients with acute cardiac
failure is unquestionably warranted.
Class IIa recommendation, level of evidence C
The use of increased concentrations of oxygen in
patients without evidence of hypoxaemia is more contro-
versial and may cause harm.63
9.2. Ventilatory support without endotracheal
intubation (non-invasive ventilation)
Two techniques are used for ventilatory support:
CPAP or non-invasive positive pressure ventilation
(NIPPV). NIPPV is a method of providing mechanical
ventilation to patients without the need for endotracheal
intubation. There is a strong consensus that one of
these two techniques should be used before
endotracheal intubation and mechanical ventilation.
Utilization of non-invasive techniques dramatically
reduce the need for endotracheal intubation and
mechanical ventilation.
9.2.1. Rationale. Application of CPAP can cause pul-
monary recruitment and is associated with an increase
in the functional residual capacity. The improved pul-
monary compliance, reduced transdiaphragmatic press-
ure swings, and decreased diaphragmatic activity can
lead to a decrease in the overall work of breathing and
therefore a decreased metabolic demand from the
body. NIPPV is a more sophisticated technique that
requires a ventilator. Addition of a PEEP to the inspiratory
assistance results in a CPAP mode (also known as bilevel
positive pressure support, BiPAP). The physiological ben-
eﬁts of this mode of ventilation are the same as for CPAP
but also include the inspiratory assist which further
reduces the work of breathing and the overall metabolic
demand.
9.2.2. Evidence for the use of CPAP and NIPPV in left
ventricular failure. CPAP in patients with cardiogenic
pulmonary oedema improves oxygenation, decreases
symptoms and signs of AHF, and results in a decreased
need for endotracheal intubation.64–68 The studies have
been relatively small and therefore have not reported a
statistically signiﬁcant reduction in mortality. A systema-
tic review69 following the ﬁrst three trials suggested
that CPAP was associated with a decreased need for intu-
bation and a trend to decreased in-hospital mortality
compared to standard therapy alone. Evidence was
lacking, however, on the potential for CPAP to actually
cause harm.
There have been three randomized controlled trials of
the use of NIPPV in the setting of acute cardiogenic pul-
monary oedema.70–72 NIPPV appears to decrease the need
for endotracheal intubation, but this does not translate
into a reduction in mortality or improvement in
long-term function.
9.2.3. Conclusions. The use of CPAP and NIPPV in acute
cardiogenic pulmonary oedema is associated with a sig-
niﬁcant reduction in the need for tracheal intubation
and mechanical ventilation.
Class IIa recommendation, level of evidence A
There are insufﬁcient data to demonstrate a signiﬁcant
reduction in mortality; however, the data do not trend in
that direction.
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9.3. Mechanical ventilation with endotracheal
intubation in AHF
Invasive mechanical ventilation (with endotracheal intu-
bation) should not be used to reverse hypoxaemia that
could be better restored by oxygen therapy, CPAP, or
NIPPV, but rather to reverse AHF-induced respiratory
muscle fatigue. The latter is the most frequent reason
for endotracheal intubation and mechanical ventilation.
Respiratory muscle fatigue may be diagnosed by a
decrease in respiratory rate, associated with hypercapnia
and confused state of mind.
Invasive mechanical ventilation should only be used if
acute respiratory failure does not respond to vasodila-
tors, oxygen therapy, and/or CPAP, or NIPPV. Another con-
sideration should be the need for immediate intervention
in a patient with pulmonary oedema secondary to
ST-elevation acute coronary syndrome.
10. Medical treatment
10.1. Morphine and its analogues in AHF
Morphine is indicated in the early stage of the treatment
of a patient admitted with severe AHF, especially if
associated with restlessness and dyspnoea.
Class IIb recommendation, level of evidence B
Morphine induces venodilatation and mild arterial dila-
tation, and reduces heart rate.73 In most studies, iv
boluses of morphine 3 mg were administered as soon
as the intravenous line was inserted. This dosing can be
repeated if required.
10.2. Anticoagulation
Anticoagulation is well established in acute coronary
syndrome with or without heart failure.29 The same is
true in atrial ﬁbrillation.31 There is less evidence
for the initiation of unfractionated heparin or low
molecular weight heparin (LMWH) in AHF. A large
placebo-controlled trial of enoxaparine 40 mg subcuta-
neoulsy in acutely ill and hospitalized patients, including
a major group of heart failure patients, showed no clini-
cal improvement but less venous thrombosis.74 There
are no large comparative studies comparing LMWH to
unfractionated heparin (given as 5000 IU twice or thrice
daily). Careful monitoring of the coagulation system
is mandatory in AHF as there is often concomitant liver
dysfunction. LMWH is contraindicated if the creatinine
clearance is below 30 mL/min or should be used with
extreme care with monitoring of the anti-Factor Xa level.
10.3. Vasodilators in the treatment of AHF
Vasodilators are indicated in most patients with acute
heart failure as ﬁrst line therapy, if hypoperfusion is
associated with an adequate blood pressure and signs
of congestion with low diuresis, to open the peripheral
circulation and to lower pre-load (Table 6 ).
10.3.1. Nitrates. Nitrates relieve pulmonary congestion
without compromising stroke volume or increasing myo-
cardial oxygen demand in acute left heart failure, par-
ticularly in patients with acute coronary syndrome. At
low doses they only induce venodilation, but as the
dose is gradually increased they cause the arteries,
including the coronary arteries, to dilate. With appropri-
ate doses, nitrates exert balanced vasodilation of the
venous and arterial sides of the circulation, thereby
reducing LV pre-load and after-load, without impairing
tissue perfusion. Their effect on cardiac output depends
on pre-treatment pre-load and after-load and the
ability of the heart to respond to baroreceptor-induced
increases in sympathetic tone.
Initially nitrates may be given orally but intravenous
nitrates are also well tolerated in AMI. Two randomized
trials in AHF have established the efﬁcacy of intravenous
nitrates in combination with furosemide and have
demonstrated that titration to the highest haemodynami-
cally tolerable dose of nitrates with low dose furosemide
is superior to high dose diuretic treatment alone.
Class I recommendation, level of evidence B
In one of these randomized studies furosemide and
isosorbide dinitrate as bolus injections were tested and
it was reported that intravenous high dose nitrate was
more effective than furosemide treatment in controlling
severe pulmonary oedema.75
Table 6 Indications and dosing of vasodilators in AHF
Vasodilator Indication Dosing Main side effects Other
Glyceryl trinitrate,
5-mononitrate
Acute heart failure,
when blood
pressure is adequate
Start 20 mg/min, increase
to 200 mg/min
Hypotension,
headache
Tolerance on
continuous use
Isosorbide dinitrate Acute heart failure,
when blood pressure
is adequate
Start with 1 mg/h,
increase to 10 mg/h
Hypotension,
headache
Tolerance on
continuous use
Nitroprusside Hypertensive crisis,
cardiogenic shock
combined with
intoropes
0.3–5mg/kg/min Hypotension,
isocyanate toxicity
Drug is light sensitive
Nesiritidea Acute decompensated
heart failure
Bolus 2 mg/kg þ infusion
0.015–0.03 mg/kg/min
Hypotension
aLimited sales approval in ESC countries.
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In practical use nitrates have a U-shaped curve effect.
If given in sub-optimal doses vasodilators may have a
limited effect in preventing AHF recurrences. However,
administration of high doses may also reduce their
effectiveness. One disadvantage of nitrates is the rapid
development of tolerance especially when given intra-
venously in high doses, limiting their effectiveness to
16–24 h only. Nitrates should be given at doses aimed
at achieving optimal vasodilation, leading to an increase
in cardiac index (CI) and decrease in pulmonary wedge
pressure. Inappropriate vasodilation may induce a steep
reduction in blood pressure, which may result in haemo-
dynamic instability.
Nitroglycerin can be administered orally or by inhala-
tion [glyceryl trinitrate (GTN) spray 400 mg (2 puffs)
every 5–10 min], or buccally (isosorbide dinitrate 1 or
3 mg), while monitoring blood pressure. The intravenous
administration and dosing of nitrates (glycerylnitrate
20 mg/min increasing dose to 200 mg/min, or isosorbide
dinitrate 1–10 mg/h) should be done with extreme
caution, under careful blood pressure monitoring, titrat-
ing the dose administered against blood pressure
decrease. One should be particularly cautious when
administering nitrates to a patient with aortic stenosis,
although this therapy may help in these complex situ-
ations. The dose of nitrates should be reduced if systolic
blood pressure falls below 90–100 mmHg and discontin-
ued permanently if blood pressure drops further. From
a practical point of view a reduction of 10 mmHg in
mean arterial pressure should be achieved.
10.3.2. Sodium nitroprusside. Sodium nitroprusside
(SNP) (0.3 mg/kg/min up-titrating carefully to 1 mg/kg/
min up to 5 mg/kg/min) is recommended in patients
with severe heart failure, and in patients with predomi-
nantly increased after-load such as hypertensive heart
failure or mitral regurgitation.
Class I recommendation, level of evidence C
SNP should be titrated cautiously and usually requires
invasive arterial monitoring and close supervision. Pro-
longed administration may be associated with toxicity
from its metabolites, thiocyanide and cyanide, and
should be avoided especially in patients with severe
renal or hepatic failure. Controlled trials with SNP in
AHF are lacking and its administration in AMI has
yielded equivocal results.76 SNP should be tapered
down to avoid rebound effects. In AHF caused by acute
coronary syndromes, nitrates are favoured over SNP as
SNP may cause ‘coronary steal syndrome’.77,78
10.3.3. Nesiritide. Recently, nesiritide, a new class
of vasodilator, has been developed for the treatment of
AHF.40 Nesiritide is a recombinant human brain or
B-type natriuretic peptide (BNP) that is identical to the
endogenous hormone. Nesiritide has venous, arterial,
and coronary vasodilatory properties that reduce pre-
load and after-load, and increase cardiac output without
direct inotropic effects.
Systemic infusion of nesiritide in patients with CHF
has beneﬁcial haemodynamic actions, results in an
enhanced sodium excretion, and suppression of the
renin–angiotensin–aldosterone and sympathetic nervous
systems.79 Nesiritide was compared to intravenous nitro-
glycerin and resulted in improvement in haemodynamics
more effectively and with fewer adverse effects,
although this did not translate into improvement in clini-
cal outcome. Nesiritide may cause hypotension and some
patients are non-responders.
10.3.4. Calcium antagonists. Calcium antagonists are
not recommended in the treatment of AHF. Diltiazem
and verapamil, and dihydropyridines, should be con-
sidered contraindicated.
10.4. Angiotensin converting enzyme
(ACE)-inhibitors in AHF
10.4.1. Indications. ACE-inhibitors are not indicated
in the early stabilization of patients with AHF.
Class IIb recommendation, level of evidence C
However, as these patients are at high risk, ACE-
inhibitors have a role in early management of AHF
patients and AMI. There is still debate on the selection
of patients and the timing of initiation of ACE-inhibitor
therapy.
10.4.2. Effects and mechanism of action. The haemo-
dynamic effects of ACE-inhibitors result from decreased
formation of AII and increased levels of bradykinin,
which in turn decreases total peripheral vascular resis-
tances and promotes natriuresis. Short-term treatment
is accompanied by a decrease in angiotensin II (AII) and
aldosterone and an increase in angiotensin I and plasma
renin activity.
There have been no efﬁcacy studies of ACE-inhibitors in
AHF to date. Studies with ACE-inhibitors in heart failure
after myocardial infarction have focused on long-term
effects.80,81 A recent meta-analysis found that mortality
at 30 days was reduced from 7.6% in the placebo group
to 7.1% in the ACE-inhibitor group [relative risk reduction
7% (95% CI 2–11%, P , 0.004)]. This equates to about
ﬁve fewer deaths per 1000 patients treated for 4–6
weeks [number needed to treat (NNT) to prevent one
death ¼ 200]. The trials which selected high-risk patients
found that ACE-inhibitors led to large relative and
absolute reductions in mortality.82
10.4.3. Practical use. Intravenous ACE-inhibition should
be avoided. The initial dose of the ACE-inhibitor should
be low and increased progressively after early stabiliz-
ation within 48 h with monitoring of blood pressure and
renal function. The duration of therapy, when initiated,
should be at least six weeks.
Class I recommendation, level of evidence A
ACE-inhibitors should be used with caution in patients
with marginal cardiac output as they may signiﬁcantly
reduce glomerular ﬁltration.The risk of intolerance to
the ACE-inhibitors is increased by the concomitant
administration of non-steroid anti-inﬂammatory agents,
and in the presence of bilateral renal artery stenosis.
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10.5. Diuretics
10.5.1. Indications. Administration of diuretics is indi-
cated in patients with acute and acutely decompensated
heart failure in the presence of symptoms secondary to
ﬂuid retention.
Class I recommendation, level of evidence B
The symptomatic beneﬁts and their universal clinical
acceptance have precluded a formal evaluation in
large-scale randomized clinical trials.
10.5.2. Effects and mechanisms of action. Diuretics
increase the urine volume by enhancing the excretion
of water, sodium chloride and other ions, leading to a
decrease in plasma and extracellular ﬂuid volume, total
body water and sodium, a reduction in right and left
ventricular ﬁlling pressures and a decrease in peripheral
congestion and pulmonary oedema.83,84 Intravenous
administration of loop diuretics also exerts a vasodilating
effect, manifested by an early (5–30 min) decrease in
right atrial and pulmonary wedge pressure as well as pul-
monary resistances.85 With high bolus doses (.1 mg/kg)
there is a risk of reﬂex vasoconstriction. As opposed to
chronic use of diuretics, in severe decompensated heart
failure the use of diuretics normalizes loading conditions
and may reduce neurohormonal activation in the short
term.86 Especially in acute coronary syndromes diuretics
should be used in low doses and preference given to
vasodilator therapy.87
10.5.3. Practical use. Intravenous administration of
loop diuretics (furosemide, bumetanide, torasemide),
with a strong and brisk diuretic effect is the preferred
choice in patients with AHF. Therapy can safely be
initiated before hospital admission75,88–90 and the dose
should be titrated according to the diuretic response
and relief of congestive symptoms. Administration of a
loading dose followed by continued infusion of furose-
mide or torasemide have been shown to be more
effective than bolus alone.87,91–95 Thiazides96–98 and spir-
onolactone99 can be used in association with loop diure-
tics, the combination in low doses being more effective
and having with fewer secondary effects than the use
of higher doses of a single drug.96–99 Combination of
loop diuretics with dobutamine, dopamine92 or nitrates88
is also a therapeutic approach that is more effective and
produces fewer secondary effects than increasing the
dose of the diuretic.100
Class IIb recommendation, level of evidence C
Table 7 lists the recommendations for the practical use
of diuretics. Table 8 gives the recommended doses of
commonly used diuretics in heart failure.
Table 8 Diuretic dosing and administration
Severity of ﬂuid retention Diuretic Dose (mg) Comments
Moderate Furosemide, or 20–40 Oral or intravenous according to
clinical symptoms
Bumetanide, or 0.5–1.0 Titrate dose according to clinical
response
Torasemide 10–20 Monitor Naþ, Kþ, creatinine and
blood pressure
Severe Furosemide, or 40–100 Intravenously
Furosemide infusion 5–40 mg/h Better than very high bolus
doses
Bumetanide, or 1–4 Orally or intravenously
Torasemide 20–100 Orally
Refractory to loop diuretics Add HCTZ, or 25–50 twice daily Combination with loop diuretic better
than very high dose of
loop diuretics alone
Metolazone, or 2.5–10 once daily Metolazone more potent if creatinine
clearance ,30 mL/min
Spironolactone 25–50 once daily Spironolactone best choice if patient
not in renal failure and
normal or low serum Kþ
In case of alkalosis Acetazolamide 0.5 Intravenously
Refractory to loop
diuretic and thiazides
Add dopamine for renal
vasodilatation, or dobutamine
as an inotropic agent
Consider ultraﬁltration or
haemodialysis if co-existing
renal failure
HCTZ ¼ hydrochlorothiazide.
Table 7 Practical use of diuretics in AHF
Start with individualized dose depending on clinical condition
(see Table 8 )
Titrate according to clinical response
Reduce dose when ﬂuid retention is controlled
Monitor serum Kþ, Naþ and renal function at frequent
intervals (every 1–2 days), according to diuretic response
Replace Kþ and Mgþ loss
In case of diuretic resistance follow suggestions in Table 10
398 ESC Guidelines
 by guest on Decem
ber 3, 2010
e
u
rheartj.oxfordjournals.org
D
ow
nloaded from
 
10.5.4. Diuretic resistance. Diuretic resistance is
deﬁned as the clinical state in which diuretic response
is diminished or lost before the therapeutic goal of
oedema relief has been achieved.101 Such resistance is
associated with a poor prognosis.102 It is more frequent
in patients with chronic, severe heart failure on long-
term diuretic therapy, although it has also been reported
with acute volume depletion after intravenous adminis-
tration of loop diuretics.103 Diuretic resistance can be
attributed to a number of factors (Table 9 ).101,103 A
number of therapeutic approaches to overcome diuretic
resistance have been explored (Table 10 ), and in clinical
practice different strategies may be of value in a particu-
lar patient. Continuous infusion of furosemide is more
effective than individual boluses.104
10.5.5. Secondary effects, drug interactions. Although
diuretics can be used safely in the majority of
patients, secondary effects are frequent and may be
life-threatening. They include neurohormonal activation,
especially of the angiotensin–aldosterone system and the
sympathetic nervous system97, hypokalaemia, hypo-
magnesaemia, and hypochloraemic alkalosis that may
lead to severe arrhythmias92, and nephrotoxicity and
aggravation of renal failure.100,105 Excessive diuresis
may reduce venous pressure, pulmonary wedge pressure
and diastolic ﬁlling excessively, leading to a reduction
in stroke volume and cardiac output, particularly in
patients with severe heart failure and predominant dias-
tolic failure or ischaemic RV dysfunction. Intravenous
administration of acetazolamide (1 or 2 doses) may be
helpful for the correction of alkalosis.106
10.5.6. New diuretic agents. Some new compounds
with diuretic and other effects are under investigation,
including vasopressin V2 receptor antagonists, brain
natriuretic peptides (see Section 10.3.3) and adenosine
receptor antagonists.
10.6. b-blocking agents
10.6.1. Indications and rationale for b-blocking agents.
There has been no study with b-blocker therapy in AHF
targeted to acutely improve the condition. On the con-
trary, AHF has been considered a contraindication for
this treatment. Patients with more than basal pulmonary
rales, or hypotension, have been excluded from trials
early after AMI. In patients with AMI who are not in
overt heart failure or hypotensive, b-blockers limit
infarct size, reduce life-threatening arrhythmias and
relieve pain.30,107–109
Intravenous administration should be considered in
patients with ischaemic chest pain resistant to opiates,
recurrent ischaemia, hypertension, tachycardia, or
arrhythmia. In the Gothenburg metoprolol study, intra-
venous metoprolol or placebo was initiated early after
an AMI and followed by oral therapy for three months.
Fewer patients developed heart failure in the metoprolol
group.110 In patients with signs of pulmonary congestion
with basal rales and/or treatment with intravenous furo-
semide, metoprolol therapy had even greater effects and
reduced mortality and morbidity.111 There is experience
with the short acting b-blocker esmolol mainly in the
setting of cardiac surgery. One small study has compared
celiprolol and esmolol in severe heart failure. Celiprolol
reduced CI less at similar heart rate reduction, which
was claimed to be due to differences in the vasodilation
effect.112 The clinical importance of this difference is
unclear. Invasive haemodynamic monitoring was carried
out in the MIAMI trial on patients with elevated pulmo-
nary wedge pressures up to 30 mmHg. These patients
when treated with metoprolol showed a decrease in
ﬁlling pressures.113
10.6.2. Practical use. In patients with overt AHF and
more than basal pulmonary rales, b-blockers should be
used cautiously. Among such patients in whom ongoing
ischaemia and tachycardia are present, intravenous
metoprolol can be considered.
Class IIb recommendation, level of evidence C
However, in patients with an AMI who stabilize after
developing AHF, b-blockers should be initiated early.
Class IIa recommendation, level of evidence B
In patients with chronic heart failure, b-blockers should
be initiated when the patient has stabilized after the
acute episode (usually after 4 days).
Class I recommendation, level of evidence A
Table 10 Managing resistance to diuretics
Restrict Naþ/H2O intake and follow electrolytes
113
Volume repletion in cases of hypovolaemia113
Increase dose and/or frequency of administration of
diuretic109,116
Use intravenous administration (more effective
than oral)113 as bolus, or as intravenous infusion (more
effective than high dose intravenous bolus)103–107,116
Combine diuretic therapy108
furosemideþ HCTZ109
furosemideþ spironolactone111
metolazoneþ furosemide (this combination is also
active in renal failure)110,107
Combine diuretic therapy with dopamine112,
or dobutamine117
Reduce the dose of ACE-inhibitor118 or use very low doses
of ACE-inhibitor118,119
Consider ultraﬁltration or dialysis if
response to above strategies ineffective120
Table 9 Causes of diuretic resistance
Intravascular volume depletion
Neurohormonal activation
Rebound Naþ uptake after volume loss
Hypertrophy of distal nephron
Reduced tubular secretion (renal failure, NSAIDs)
Decreased renal perfusion (low output)
Impaired gut absorption of an oral diuretic
Non-compliance with drugs or diet (high sodium intake)
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The initial oral dose of bisoprolol, carvedilol, or meto-
prolol should be small and increased slowly and progress-
ively to the target dose used in the large clinical trials.
Up-titration should be adapted to individual response.
b-blockers may reduce blood pressure and heart rate
excessively. As a general rule, patients on b-blockers
admitted to hospital due to worsening heart failure
should be continued on this therapy unless inotropic
support is needed but the dose could be reduced if
signs of excessive dosage are suspected (i.e. bradycardia
and hypotension).
10.7. Inotropic agents
10.7.1. Clinical indications. Inotropic agents are
indicated in the presence of peripheral hypoperfusion
(hypotension, decreased renal function) with or without
congestion or pulmonary oedema refractory to diuretics
and vasodilators at optimal doses (Figure 6 ).
Class IIa recommendation, level of evidence C
Their use is potentially harmful as they increase oxygen
demand and calcium loading and they should be used
with caution.114
In patients with decompensated CHF the symptoms,
clinical course, and prognosis of the disease may
become critically dependent on the haemodynamics.
Thus, improvements in the haemodynamic parameters
may become a goal of treatment and inotropic agents
may be useful and life-saving in this setting. The bene-
ﬁcial effects of an improvement in the haemodynamic
parameters is, however, partially counteracted by the
risks of arrhythmias and, in some cases, myocardial
ischaemia and by the possible long-term progression of
myocardial dysfunction caused by an excessive increase
in energy expenditure.114,115 The risk-beneﬁt ratio
may not, however, be the same for all the inotropic
agents. Those acting through the stimulation of the
b1-adrenergic receptors which increase cytoplasmic
myocardial cell Caþþ concentration may be associated
with the greatest risk.116,117 Lastly, only a few controlled
trials with inotropic agents in patients with AHF have
been performed, and very few have assessed their
effects on the symptoms and signs of heart failure and
their long-term effects on prognosis.117
10.7.2. Dopamine. At low doses (,2 mg/kg/min i.v.)
dopamine acts only on peripheral dopaminergic recep-
tors and lowers peripheral resistance both directly and
indirectly. Vasodilation occurs predominantly in the
renal, splanchnic, coronary, and cerebral vascular beds.
At this dosage, its action may cause an improvement in
renal blood ﬂow, glomerular ﬁltration rate, diuresis,
and sodium excretion rate, with an increased response
to diuretic agents, in patients with renal hypoperfusion
and failure.118–121
At higher doses (.2 mg/kg/min i.v.) dopamine stimu-
lates the b-adrenergic receptors both directly and
indirectly with a consequent increase in myocardial con-
tractility and cardiac output. At doses .5 mg/kg/min
dopamine acts on a-adrenergic receptors with an
increase in the peripheral vascular resistance which,
Figure 6 Rationale for inotropic drugs in AHF.
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though potentially useful in hypotensive patients, may be
deleterious in patients with AHF, as it may augment the
LV after-load, pulmonary artery pressure, and pulmonary
resistance.122
10.7.3. Dobutamine. Dobutamine is a positive inotropic
agent acting mainly through stimulation of b1-receptors
and b2-receptors to produce dose-dependent positive
inotropic and chronotropic effects,123,124 and a reﬂex
decrease in sympathetic tone, and thus vascular resis-
tance.125 The resultant beneﬁt may therefore differ
from patient to patient. At low doses, dobutamine
induces mild arterial vasodilatation, which augments
stroke volume by reductions in after-load. At higher
doses dobutamine causes vasoconstriction.77
Heart rate is generally increased in a dose-dependent
manner to a lesser extent than with other cathechol-
amines. However, in patients with atrial ﬁbrillation,
heart rate may be increased to undesirable rates, due
to facilitation of atrioventricular (AV) conduction. Sys-
temic arterial pressure usually increases slightly, but
may remain stable, or decrease. Similarly pulmonary
arterial pressure and capillary wedge pressure usually
decrease, but may remain stable or even increase in
some patients with heart failure.119,122,126
The improved diuresis observed during dobutamine
infusion in patients with heart failure is the result of
increased renal blood ﬂow in response to improved
cardiac output.
10.7.4. Practical use. Dopamine may be used as an
inotrope (.2 mg/kg/min i.v.) in AHF with hypotension.
Infusion of low doses of dopamine (2–3 mg/kg/min)
may be used to improve renal blood ﬂow and diuresis
in decompensated heart failure with hypotension and
low urine output. However if no response is seen the
therapy should be terminated127 (Table 11 ).
Class of recommendation IIb, level of evidence C
Dobutamine is currently indicated when there is
evidence of peripheral hypoperfusion (hypotension,
decreased renal function) with or without congestion or
pulmonary oedema refractory to diuretics and vasodila-
tors at optimal doses (Table 11 ).
Class IIa recommendation, level of evidence C
Dobutamine is used to increase the cardiac output. It is
usually initiated with a 2–3 mg/kg/min infusion rate
without a loading dose. The infusion rate may then be
progressively modiﬁed according to symptoms, diuretic
response, or haemodynamic monitoring. Its haemo-
dynamic actions are proportional to its dosage, which
can be increased to 20 mg/kg/min. The elimination of
the drug is rapid after cessation of infusion, making it a
very convenient inotropic agent.
In patients receiving b-blocker therapy with metopro-
lol, dobutamine doses have to be increased as high as
15–20 mg/kg/min to restore its inotropic effect.128 The
effect of dobutamine differs in patients receiving carve-
dilol: it can lead to an increase in pulmonary vascular
resistance during the infusion of increasing doses of
dobutamine (5–20 mg/kg/min).129
Based on haemodynamic data alone, the inotropic effect
of dobutamine is additive to that of phosphodieasterase
inhibitors (PDEI); the combination of PDEI and dobuta-
mine produces a positive inotropic effect greater than
either drug alone.129,130
Prolonged infusion of dobutamine (above 24–48 h) is
associated with tolerance and partial loss of haemo-
dynamic effects.122 Weaning from dobutamine may be
difﬁcult because of recurrence of hypotension, conges-
tion, or renal insufﬁciency. This can sometimes be
solved by very progressive tapering of dobutamine (i.e.
decrease in dosage by steps of 2 mg/kg/min every other
day) and optimization of oral vasodilator therapy such
as with hydralazine and/or an ACE-inhibitor.131 It is some-
times necessary to tolerate some renal insufﬁciency or
hypotension during this phase.
Infusion of dobutamine is accompanied by an increased
incidence of arrhythmia originating from both ventricles
and atria. This effect is dose-related and may be more
prominent than with PDEI132,133 and should prompt
Table 11 Administration of positive inotropic agents
Bolus Infusion rate
Dobutamine No 2 to 20 mg/kg/min (bþ)
Dopamine No ,3 mg/kg/min: renal effect (dþ)
3–5 mg/kg/min: inotropic (bþ)
.5 mg/kg/min: (bþ), vasopressor (aþ)
Milrinone 25–75 mg/kg over 10–20 min 0.375–0.75 mg/kg/min
Enoximone 0.25–0.75 mg/kg 1.25–7.5 mg/kg/min
Levosimendan 12–24 mg/kga over 10 min 0.1 mg/kg/min which can be decreased
to 0.05 or increased to
0.2 mg/kg/min
Norepinephrine No bolus 0.2–1.0 mg/kg/min
Epinephrine Bolus: 1 mg can be given i.v.
at resuscitation, may be repeated after
3–5 min, endotracheal route is not
favoured
0.05–0.5 mg/kg/min
aCurrent recommended dosing. In patients with hypotension, therapy should be started without a bolus.
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strict potassium compensation during intravenous diure-
tic use. Tachycardia may also be a limiting parameter,
and dobutamine infusion may trigger chest pain in
patients with coronary artery disease. In patients with
hibernating myocardium dobutamine appears to increase
contractility in the short term at the expense of myocyte
necrosis and loss in myocardial recovery.134 There are no
controlled trials on dobutamine in AHF patients and some
trials show unfavourable effects with increased untoward
cardiovascular events.42,116
10.7.5. Phosphodiesterase inhibitors. Milrinone and
enoximone are the two Type III phosphodiesterase
inhibitors (PDEIs) used in clinical practice. In AHF, these
agents have signiﬁcant inotropic, lusitropic, and peri-
pheral vasodilating effects with an increase in cardiac
output and stroke volume, and a concomitant decline in
pulmonary artery pressure, pulmonary wedge pressure,
systemic and pulmonary vascular resistance.122,135 Their
haemodynamic proﬁle is intermediate between that of
a pure vasodilator, like nitroprusside, and that of a pre-
dominant inotropic agent, like dobutamine.126 As their
site of action is distal to the beta-adrenergic receptors,
PDEIs maintain their effects even during concomitant
b-blocker therapy.128,129,136
Type III PDEIs are indicated when there is evidence of
peripheral hypoperfusion with or without congestion
refractory to diuretics and vasodilators at optimal
doses, and preserved systemic blood pressure.
Class of recommendation IIb, level of evidence C
These agents may be preferred to dobutamine in
patients on concomitant b-blocker therapy, and/or with
an inadequate response to dobutamine.
Class of recommendation IIa, level of evidence C
In practical use milrinone is administered as a 25 mg/kg
bolus over 10–20 min, followed by a continuous infusion
at 0.375–0.75 mg/kg/min. Similarly, enoximone is admi-
nistered as a bolus of 0.25–0.75 mg/kg followed by a con-
tinuous infusion at 1.25–7.5 mg/kg/min (Table 11 ).
Hypotension caused by excessive peripheral venodilation
is an untoward effect observed mainly in patients with
low ﬁlling pressures. It may be avoided by starting the
infusion without any bolus. Thrombocytopaenia is uncom-
mon with both milrinone (0.4%) and enoximone.
The data regarding the effects of PDEI administration
on the outcome of patients with AHF are insufﬁcient,
but raise concerns about safety, particularly in patients
with ischaemic heart failure.54,117,137
10.7.6. Levosimendan. Levosimendan has two main
mechanisms of action: Caþþ sensitization of the contrac-
tile proteins responsible for a positive inotropic action,
and smooth muscle Kþ channel opening responsible for
peripheral vasodilation. Some data suggest levosimendan
may also have a phosphodioesterase inhibition effect.
Levosimendan has a potent acetylated metabolite that
is also a Caþþ-concentration dependent Caþþ sensitizer.
Its half-life is 80 h, which probably explains the
prolonged haemodynamic effects of a 24 h levosimendan
infusion.138,139
Levosimendan is indicated in patients with sympto-
matic low cardiac output heart failure secondary to
cardiac systolic dysfunction without severe hypotension
(Table 11 ).
Class of recommendation IIa, level of evidence B
Levosimendan is generally administered as a conti-
nuous intravenous infusion at a dose of
0.05–0.1 mg/kg/min preceded by a loading dose of
12–24 mg/kg, administered over 10 min.42,140–142 Its
haemodynamic effects are dose-dependent and the infu-
sion rate may be up-titrated to a maximal rate of
0.2 mg/kg/min.165 Most of the clinical data have been
obtained with intravenous infusions lasting from 6 h142 to
24 h,42,141 but the haemodynamic effects persist for
.48 h after the end of the infusion.138,143
Levosimendan infusion in patients with acutely decom-
pensated heart failure caused by left ventricular systolic
dysfunction has been associated with a dose-dependent
increase in the cardiac output and stroke volume, a
decline in the pulmonary wedge pressure, systemic
vascular resistance, and pulmonary vascular resistance,
and a slight increase in the heart rate, and decrease in
the blood pressure.42,143 An improvement in symptoms
of dyspnoea and fatigue and a favourable outcome has
been shown in randomized trials comparing levosimendan
with dobutamine.42 Differently from dobutamine, the
haemodynamic response to levosimendan is maintained,
or even of greater magnitude, in the patients on conco-
mitant b-blocker therapy.42
Tachycardia and hypotension are described with
high-dose levosimendan infusion42 and it is not currently
recommended in patients with a systolic blood pressure
,85 mmHg.143 Levosimendan has not been associated
with an increased frequency of malignant arrhythmias
in comparative trials with either placebo,141,142 or
dobutamine.42 Reductions in the haematocrit, haemo-
globin, and plasma potassium, likely secondary to vasodi-
lation and secondary neurohumoral activation, have been
described42,143 and seem to be dose-dependent.143
10.7.7. Vasopressor therapy in cardiogenic shock. When
the combination of inotropic agent and ﬂuid challenge
fails to restore adequate arterial and organ perfusion
despite an improvement in cardiac output, therapy with
vasopressors may be required. Vasopressors may also be
used, in emergencies, to sustain life and maintain per-
fusion in the face of life-threatening hypotension. Since
cardiogenic shock is associated with high vascular resist-
ances, any vasopressor should be used with caution and
only transiently, because it may increase the after-load
of a failing heart and further decrease end-organ blood
ﬂow.
10.7.7.1. Epinephrine. Epinephrine is a catecholamine
with high afﬁnity for b1, b2, and a receptors. Epinephrine
is used generally as an infusion at doses of 0.05 to 0.5 mg/
kg/min when dobutamine refractoriness is present and
the blood pressure remains low. Direct arterial pressure
402 ESC Guidelines
 by guest on Decem
ber 3, 2010
e
u
rheartj.oxfordjournals.org
D
ow
nloaded from
 
monitoring and monitoring of haemodynamic response by
PAC is recommended (Table 11 ).
10.7.7.2. Norepinephrine. Norepinehrine is a catechol-
amine with high afﬁnity for a-receptors and is generally
used to increase systemic vascular resistance. Norepi-
nephrine-induced increases in heart rate are less than
with epinephrine. The dosing is similar to epinephrine.
Norepinephrine (0.2 to 1 mg/kg/min) is favoured in situ-
ations with low blood pressure related to reduced sys-
temic vascular resistance such as septic shock.
Norepinephrine is often combined with dobutamine to
improve haemodynamics.144 Norepinehrine may reduce
end-organ perfusion.
10.7.8. Cardiac glycosides. Cardiac glycosides inhibit
myocardial Naþ/Kþ ATPase, thereby increasing Caþþ/
Naþ exchange mechanisms, producing a positive inotro-
pic effect. In heart failure the positive inotropic effect
following b-adrenergic stimulation is attenuated and
the positive force–frequency relationship is impaired. In
contrast to b-adrenoceptor agonists, the positive inotro-
pic effect of cardiac glycosides is unchanged in failing
hearts144 and the force–frequency relationship is par-
tially restored.145 In chronic heart failure, cardiac glyco-
sides reduce symptoms and improve clinical status,
thereby decreasing the risk of hospitalization for heart
failure without effects on survival.146,147 In AHF, cardiac
glycosides produce a small increase in cardiac output148
and a reduction of ﬁlling pressures.149 In patients
with severe heart failure following episodes of acute
decompensation, cardiac glycosides have been shown
to be efﬁcacious in reducing the re-occurrence of
acute decompensation.150 Predictors for these bene-
ﬁcial effects are a third heart sound, extensive LV
dilatation and distended jugular veins during the AHF
episode.
However, in patients following myocardial infarction
with heart failure, a substudy of the AIRE-Investigation
has shown adverse effects on outcome after AMI
accompanied by heart failure.151 Furthermore, following
AMI an increase of creatinine kinase was more pro-
nounced in patients receiving cardiac glycosides.152 In
addition, for patients with myocardial infarction and
AHF, the use of digitalis was a predictor for
life-threatening pro-arrhythmic events.153 Therefore,
inotropic support with cardiac glycosides cannot be rec-
ommended in AHF, in particular following myocardial
infarction.
An indication for cardiac glycosides in AHF may be
tachycardia-induced heart failure e.g. in atrial ﬁbrilla-
tion with insufﬁcient rate-control by other agents such
as b-blockers. Rigorous control of heart rate in tachyar-
rhythmia during the course of AHF can control heart
failure symptoms.154 Contraindications to the use of
cardiac glycosides include bradycardia, second and
third degree AV-block, sick sinus syndrome, carotid
sinus syndrome, Wolff–Parkinson–White syndrome,
hypertrophic obstructive cardiomyopathy, hypokalaemia,
and hypercalcaemia.
11. Underlying diseases and co-morbidities
in AHF
There are several acute morbidities, which can cause de
novo AHF or trigger decompensation in CHF. Coronary
heart disease and acute coronary syndromes are
the most frequent causes for AHF. Non-cardiac
co-morbidities may also signiﬁcantly complicate the
therapy of AHF.
11.1. Coronary artery disease
In acute coronary syndromes (unstable angina or myocar-
dial infarction) complicated by AHF, coronary angio-
graphy is indicated (Figure 7 ). In AMI, reperfusion may
signiﬁcantly improve or prevent AHF.29,30 Emergency per-
cutaneous coronary intervention (PCI), or on occasion
surgery, should be considered at an early stage and per-
formed as indicated. If neither PCI nor surgery are
readily available or can only be provided after a long
delay, early ﬁbrinolytic therapy is recommended.29,30
All patients with AMI and signs and symptoms of heart
failure should undergo an echocardiographic study to
assess regional and global ventricular function, asso-
ciated valve dysfunction (mainly mitral regurgitation)
and to rule out other disease states (e.g. perimyocarditis,
cardiomyopathy, and pulmonary embolism).
Class of recommendation I, level of evidence C
Special tests to provide evidence of reversible myocar-
dial ischaemia are sometimes necessary.
In cardiogenic shock caused by acute coronary syn-
dromes coronary angiography and revascularization
should be performed as soon as possible.155
Class I recommendation, level of evidence A
Temporary stabilization of the patient can be achieved
by adequate ﬂuid replacement, intra-aortic balloon
counter-pulsation, pharmacological inotropic support,
nitrates and artiﬁcial ventilation. Repeated blood
samples for monitoring of electrolytes, glucose, renal
function, and arterial blood gases should be taken, par-
ticularly in diabetic patients.
Metabolic support with high-dose glucose, insulin, and
potassium cannot be recommended (except in diabetic
patients) until the results from larger-scale studies in
AMI become available.156
Class II recommendation, level of evidence A
When the haemodynamic state continues to be
unstable for several hours, the introduction of an
in-dwelling PAC may be considered. Repeated measure-
ments of mixed venous blood oxygen saturation from
the PAC can be helpful.
Class II recommendation, level of evidence B
When all these measures fail to achieve stabilization of
the haemodynamic status, mechanical support with a LV
assist device should be considered, particularly if heart
transplantation is contemplated.
In left heart failure/pulmonary oedema the acute
management is similar to that for other causes of
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Figure 7 Algorithm: AHF in AMI. IABP ¼ intra-aortic balloon pump; VSR ¼ ventricular septal rupture; PAC ¼ pulmonary artery catheterization; TEE ¼
trans-esophageal echocardiography; EF ¼ ejection fraction; MR ¼ mitral regurgitation; IVS ¼ intraventricular septum; SAM ¼ systolic anterior movement;
RA ¼ right atrium; RV ¼ right ventricle; PCI ¼ percutaneous coronary intervention; Qp:Qs ¼ pulmonary circulation volume:systemic circulation volume.
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pulmonary oedema. Inotropic agents may be deleterious.
Intra-aortic balloon counter-pulsation (IABC) should be
considered.155,157,158
The long-term management strategy should include
adequate coronary revascularization and, where there
is evidence of reduced LV function, long-term treat-
ment with renin angiotensin aldosterone system
(RAAS)-inhibition and b-blockade should follow.
Acute right heart failure is usually related to acute
RV ischaemia in acute coronary syndromes, particularly
RV infarction with a characteristic electro- and
echo-cardiogram. Early revascularization of the right
coronary artery and its ventricular branches is rec-
ommended. Supportive treatment should focus on
ﬂuid-loading and inotropic support.
11.2. Valvular disease
AHF can be caused by valvular conditions unrelated
to acute coronary syndromes, such as acute mitral or
aortic valve incompetence, acute valve incompetence
from endocarditis, aortic or mitral stenosis, thrombosis
of a prosthetic valve, or aortic dissection.
In patients with endocarditis, treatment is initially
conservative with antibiotics and other medical means
of treatment of AHF. Cardiac dysfunction may be aggra-
vated by myocarditis. However, acute valve incompe-
tence is the most common cause of AHF in patients
with infective endocarditis. Heart failure should be
promptly treated. Rapid diagnosis and therapeutic
decisions require expert consultation. Surgical consul-
tations are warranted. Surgical intervention should be
performed early in severe acute aortic or mitral regurgi-
tation (ML).
Urgent surgery is indicated in patients with endocardi-
tis and severe acute aortic regurgitation.159–163
11.3. Management of AHF due to prosthetic valve
thrombosis (PVT)
AHF from prosthetic valve thrombosis is associated with a
high mortality.164–167 All patients with heart failure symp-
toms and suspected PVTshould undergo chest ﬂuoroscopy
and an echocardiographic study (transthoracic and/or
transoesophageal if visualization of the prosthetic valve
area is inadequate).
Class I recommendation, level of evidence B
The management remains controversial. Thrombolysis
is used for right-sided prosthetic valves, and for
high-risk surgical candidates. Surgery is preferred for
left-sided PVT.
Class IIa recommendation, level of evidence B
Thrombolytic therapy is not effective when ﬁbrous
tissue ingrowth (pannus) is implicated in the obstruction
with minor secondary thrombosis.
In patients with very large and/or mobile thrombi,
thrombolytic therapy is associated with a much higher
risk for major embolism and stroke. In all these patients
surgical intervention should be considered as an alterna-
tive. Before deciding therapy, pannus formation or
structural defects of the prosthetic valve should be
ruled out by transoesophageal echocardiography.168
Echocardiography should be performed in all patients
after thrombolytic therapy. Surgical intervention should
be considered in all cases if thrombolysis fails to
resolve the obstruction although repeated infusions of
thrombolytic therapy are an alternative.166,169
The thrombolytics used are: rtPA 10-mg iv bolus fol-
lowed by 90 mg infused over 90 min; streptokinase
250–5 00 000 IU over 20 min followed by 1–1.5 million
IU infused over 10 h. After thrombolysis, unfractionated
heparin should be administered by intravenous infusion
in all patients (activated partial thromboplastin time
1.5–2.0 times control). Urokinase is also an alternative
in a dose of 4400 IU/kg/h without heparin for 12 h or
2000 IU/kg/h with heparin for 24 h.
11.4. Aortic dissection
Acute aortic dissection (particularly Type 1) may present
with symptoms of heart failure with or without pain.170
Following a period of pain, heart failure may become
the main symptom.170 The AHF is usually related to a
hypertensive crisis (see Section 11.6) or acute aortic
valve incompetence. Immediate diagnosis and surgical
consultation are warranted. Transoesophageal echocar-
diography is the best technique to assess the morphology
and function of the valve.170 Speed in surgical interven-
tion is usually vital.
11.5. AHF and hypertension
AHF is one of the well-known complications of hyperten-
sive emergencies. The clinical signs of AHF associated
with a hypertensive crisis are almost exclusively the
signs of pulmonary congestion, which may be mild or
very severe with acute pulmonary oedema throughout
both lungs. It is called ‘ﬂash pulmonary oedema’
because of its rapid onset. Rapid treatment with speciﬁc
interventions is required.
Systolic function is often preserved in patients hospi-
talized with pulmonary oedema and hypertension [more
than half of patients have a left ventricular ejection frac-
tion (LVEF) . 45%]. By contrast, diastolic abnormalities
with decreased LV compliance are often present.171,172
The goals of the treatment of acute pulmonary oedema
with hypertension are reduction in LV pre-load and
after-load, reduction of cardiac ischaemia, and mainten-
ance of adequate ventilation with clearing of the
oedema. Treatment should be started immediately and
in the following order: O2 therapy; CPAP or non-invasive
ventilation and if necessary, invasive mechanical venti-
lation, for usually a very short period; and administration
of intravenous antihypertensive agent(s).
Antihypertensive therapy should aim for an initial rapid
(within a couple of minutes) reduction of systolic or dia-
stolic BP of 30 mmHg, followed by a more progressive
decrease of BP to the values measured before the hyper-
tensive crisis: this may take several hours. No attempt
should be made to restore normal values of BP as this
may cause deterioration in organ perfusion. The initial
rapid reduction of BP may be achieved by the following
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medications given alone, or combined, if hypertension
persists: (i) intravenous loop diuretics, particularly if
the patient is clearly ﬂuid overloaded with a long
history of CHF; (ii) intravenous nitroglycerin or nitroprus-
side to decrease venous pre-load and arterial after-load,
and increase coronary blood ﬂow; (iii) a calcium-channel
blocker (such as nicardipine) may be considered as these
patients usually have diastolic dysfunction with an
increased after-load.
b-blockers should not be advised in cases of concomi-
tant pulmonary oedema. However, in some cases, and
particularly in hypertensive crisis related to phaeo-
chromocytoma, intravenous labetalol, given as slow
boluses of 10 mg whilst monitoring heart rate and blood
pressure, and followed by an infusion of 50–200 mg/h,
can be effective.
11.6. Renal failure
Heart failure and renal failure frequently co-exist,176–178
and either may cause the other. Heart failure causes
renal hypoperfusion both directly and through the acti-
vation of neurohumoral mechanisms.176 Concomitant
therapy with diuretics, ACE-inhibitors, and non-steroid
anti-inﬂammatory agents may also contribute to the
development of renal failure.
Urinalysis may vary depending on the cause of renal
failure. When renal failure is secondary to hypoperfusion,
the urinary sodium/potassium ratio is characteristically
,1. Acute tubular necrosis may be diagnosed on the
basis of an increase in urinary sodium, reduction in
urine nitrogen concentration and typical urinary sedi-
mentation ﬁndings.
A mild-to-moderate impairment in renal function is
generally asymptomatic and well tolerated. However,
even a mild-to-moderate increase in serum creatinine
and/or decrease in glomerular ﬁltration rate (GFR) are
independently associated with a worse prognosis.177,178
Concomitant acute renal failure requires the recog-
nition and treatment of its associated disorders:
anaemia, electrolyte abnormalities, and metabolic acido-
sis. Electrolyte abnormalities (hypo- and hyperkalaemia,
and hypo- and hypermagnesaemia) and metabolic acido-
sis should be corrected as they may cause arrhythmias,
reduce the response to treatment, and worsen the
prognosis.179
Renal failure also inﬂuences the response and tolera-
bility of heart failure treatments, namely digoxin and
ACE-inhibitors, angiotensin receptor blockers, and spiro-
nolactone. Also pre-renal artery stenosis and post-renal
obstructions should be assessed. Administration of
ACE-inhibitors is associated with an increased incidence
of severe renal failure and hyperkalaemia in patients
with concomitant renal failure. An increase in serum
creatinine of more than 25–30%, and/or achievement of
levels .3.5 mg/dL (.266 mmol/L) are relative contrain-
dications to the continuation of ACE-inhibitor treatment
(see Section 10.3.5.)
Moderate-to-severe renal failure [e.g. a serum creati-
nine .2.5–3 mg/dL (.190–226 mmol/L)] is also associ-
ated with a reduced response to diuretics—a signiﬁcant
predictor of mortality in heart failure patients.102 In
such patients, it may be necessary to progressively
increase the dose of the loop diuretics and/or add a
diuretic with a different mechanism of action (e.g.
metozalone). This may, however, be associated with
hypokalaemia and a further decline in GFR.
In patients with severe renal dysfunction and
refractory ﬂuid retention, continuous veno-venous
haemoﬁltration (CVVH) may become necessary. Com-
bined with a positive inotropic agent this may increase
renal blood blow, improve renal function, and restore
diuretic efﬁciency. This has been associated with an
increase in urine output, a reduction in symptoms, in
left and right ventricular ﬁlling pressures, and symp-
athetic stimulation, and with an improvement in lung
mechanical function, laboratory abnormalities (hypona-
traemia), and response to diuretic therapy.180 Loss of
renal function may require dialysis treatment especially
in the presence of hyponatraemia, acidosis, and overt
uncontrolled ﬂuid retention. The choice between peri-
toneal dialysis, haemodialysis, or ﬁltration, is usually
dependent on technical availability and on baseline
blood pressure.181
Patients with heart failure are at the highest risk of
renal damage after the administration of contrast
media. The most widely used preventive measure, e.g.
pre-procedural and post-procedural hydration, may not
be tolerated and the osmotic and volume overload of
contrast material may favour pulmonary oedema. Other
preventive measures that may be better-tolerated
include the use of the smallest possible amount of
iso-osmotic contrast media, avoidance of nephrotoxic
drugs like non-steroidal anti-inﬂammatory agents,
and pre-treatment with N-acetylcysteine,182,183 and/or
the selective DA1 receptor agonist fenoldopam.
184
Peri-procedural haemodialysis is effective at preventing
nephropathy in patients with severe renal dysfunction.185
Class IIb recommendation, level of evidence B
11.7. Pulmonary diseases and bronchoconstriction
When bronchoconstriction is present in patients with AHF,
bronchodilators should be used. This is often the case in
patients with concomitant lung problems e.g. asthma,
chronic obstructive bronchitis,186 and lung infections.
Bronchodilators may improve cardiac function, but
should not be used instead of relevant AHF treatment.
Initial treatment usually consists of 2.5 mg albuterol (sal-
butamol) (0.5 mL of a 0.5%-solution in 2.5 mL normal
saline) by nebulization over 20 min. This may be repeated
hourly during the ﬁrst few hours of therapy and there-
after as indicated.
11.8. Arrhythmias and AHF
There are no extensive reports on the prevalence of
arrhythmias either as a cause or as a complicating factor
in acute decompensated heart failure. In the Euroheart
heart failure survey rapid atrial ﬁbrillation was observed
at index hospitalization in 9% of patients and 42% had a
history of chronic or paroxysmal atrial ﬁbrillation (AF).
Life-threatening ventricular arrhythmias were seen at
index hospitalization in 2% and in the whole study
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population they were found as a concomitant early or
acute problem in 8% of patients.5
11.8.1. Bradyarrhythmias. Bradycardia in AHF patients
occurs most often in AMI, particularly with right coronary
artery occlusion.
The treatment of bradyarrhythmias is usually initially
with atropine 0.25–0.5 mg iv, repeated when needed.
Isoproterenol 2–20 mg/min can be infused in cases of AV
dissociation with low ventricular response, but should
be avoided in ischaemic conditions. Slow ventricular
rhythm in atrial ﬁbrillation can be improved by iv theo-
phylline 0.2–0.4 mg/kg/h as a bolus and then by infusion.
A temporary pacemaker should be inserted if no response
is achieved with medical therapy.187 Ischaemia should
be treated as soon as possible before or after inserting
a pacemaker as indicated188–190 (Table 12 ).
Class IIa recommendation, level of evidence C
11.8.2. Supraventricular tachycardia (SVT). Supraven-
tricular tachyarrhythmias may complicate or cause
AHF.191 On rare occasions persistent atrial tachycardias
may cause decompensated heart failure requiring
hospitalization. Similarly, atrial ﬁbrillation with a rapid
ventricular response may be the cause for a dilated
cardiomyopathy and AHF.
11.8.3. Recommendations for treatment of supraven-
tricular tachyarrhythmias in AHF. The control of the
ventricular rate response is important in patients with
AF and AHF, particularly in patients with diastolic dys-
function.31
Class IIa recommendation, level of evidence A
Patients with restrictive physiology or tamponade,
however, may suddenly deteriorate with rapid heart
rate reduction. Rapid rate control or cardioversion on
clinical demand should be achieved (Table 12 ). The
therapy of AF depends on its duration.31
Patients with AHF and AF should be anticoagulated.
When AF is paroxysmal, medical or electrical cardioversion
should be considered after initial work-up and stabilization
of the patient. If the duration of the AF is more than 48 h
the patient should be anticoagulated and optimal rate
control achieved medically for 3 weeks before cardiover-
sion. If the patient is haemodynamically unstable, urgent
cardioversion is clinically mandatory, but atrial thrombus
should be excluded by transoesophageal echocardiography
prior to cardioversion.31
Verapamil and diltiazem should be avoided in acute AF
as they may worsen heart failure and cause third degree
AV block. Amiodarone and b-blocking agents have been
successfully used in AF for rate control and prevention of
recurrence.3,192
Class I recommendation, level of evidence A
Verapamil can be considered in the treatment of AF
or narrow complex SVT in patients with only slightly
reduced ventricular systolic function.
Class I anti-arrhythmic agents should be avoided in
patients with low ejection fraction and particularly in
patients who have a wide QRS complex. Dofetilide is a
new drug with promising results in medical cardioversion
and prevention of new AF, but further studies are needed
to evaluate its safety and efﬁcacy in AHF.193
b-blocking agents can be tried in SVTs when
tolerated.194,195 In wide complex tachycardia, intrave-
nous adenosine can be used in an attempt to terminate
the arrhythmia. Electrical cardioversion of SVT with
sedation should be considered in AHF with hypotension.
AHF patients with AMI and heart failure, and patients
with diastolic heart failure, do not tolerate rapid supra-
ventricular arrhythmias.
Table 12 Treatment of arrhythmias in acute heart failure
Ventricular ﬁbrillation or
pulseless ventricular tachycardia
Deﬁbrillate with 200–300–360J (preferably by biphasic deﬁbrillation with a maximum of
200J). If refractory to initial shocks inject epinephrine 1 mg or vasopressin 40 IU and/or
amiodarone 150–300 mg as injection
Ventricular tachycardia If patient is unstable cardiovert, if stable amiodarone or lidocaine can be given to achieve
medical cardioversion.
Sinus tachycardia or
supraventricular tachycardia
Use b-blocking agents when clinically and haemodynamically tolerated:
Metoprolol 5 mg intravenously as a slow bolus (can be repeated if tolerated)
Adenosine may be used to slow AV conduction or to cardiovert re-entrant tachycardia
On rare occasions:
Esmolol 0.5–1.0 mg/kg over 1 min, followed by infusion of 50–300 mg/kg/min, or
Labetalol 1–2 mg bolus, followed by infusion of 1–2 mg/min (to total of 50–200 mg).
Labetalol also indicated in AHF related to hypertensive crisis or phaeochoromcytoma,
with 10-mg boluses, to a total dose of 300 mg.
Atrial ﬁbrillation or ﬂutter Cardiovert if possible. Digoxin 0.125–0.25 mg iv, or b-blocking agent, or amiodarone, may
be used to slow AV conduction. Amiodarone may induce medical cardioversion without
compromising left ventricular haemodynamics. Patient should be heparinized.
Bradycardia Atropine 0.25–0.5 mg iv, to total of 1–2 mg.
As interim measure, isoproterenol 1 mg in 100 mL NaCl infused to a maximum of 75mL/h
(2–12mg/min).
If bradycardia is atropine-resistant, transcutaneous or transvenous pacing should be used
as an interim measure. Theophylline may be used in AMI patients with atropine-resistant
bradycardia with bolus of 0.25–0.5 mg/kg followed by infusion at 0.2–0.4 mg/kg/h
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Plasma potassium and magnesium levels should be
normalized particularly in patients with ventricular
arrhythmia.179,196
Class IIb recommendation, level of evidence B
11.8.4. Treatment of life-threatening arrhythmias.
Ventricular ﬁbrillation and ventricular tachyarry-
thmia require immediate cardioversion, with ventilator
assistance if required, and in the case of a conscious
patient, with sedation (Table 12 ).
Amiodarone and b-blocking agents can prevent repe-
tition of these arrhythmias.3,192
Class I recommendation, level of evidence A
In the case of recurrent ventricular arrhythmias
and haemodynamically unstable patients, immediate
angiography and electrophysiological testing should be
performed. In cases of a localized arrhythmic substrate,
radiofrequency ablation may eliminate the arrhythmic
tendency although the long-term effect cannot be
ascertained3,197,207 (Table 12 ).
Class IIb recommendation, level of evidence C
11.9. Peri-operative AHF
AHF in the peri-operative period is usually related to
myocardial ischaemia, which is usually silent i.e. not
associated with chest pain.
12. Surgical treatment of AHF
AHF is a severe complication of many cardiac disorders.
In some of them surgical therapy improves prognosis
if performed urgently or immediately (see Table 13 ).
Surgical options include coronary revascularization, cor-
rection of the anatomic lesions, valve replacement or
reconstruction, as well as temporary circulatory support
by means of mechanical assist devices. Echocardiography
is the most important technique in the diagnostic
work-up (see Figure 3).
12.1. AHF related to complications of AMI
12.1.1. Free wall rupture. Free wall rupture is docu-
mented in 0.8–6.2% of patients after AMI.198 Usually
sudden death occurs within minutes due to cardiac tam-
ponade and electromechanical dissociation. The diagno-
sis is rarely established before the patient’s death.
However, in some cases the presentation of free wall
rupture is sub-acute (thrombus or adhesions seal the
rupture) giving an opportunity for intervention if the con-
dition is recognized. Most of these patients have signs of
cardiogenic shock, sudden hypotension, and/or loss of
consciousness. In some patients rupture is preceded by
chest pain, nausea, emesis, new ST-segment elevation
in the infarct related leads, or T wave changes.199 All
these patients should undergo immediate echocardiogra-
phy (Figure 7 ). The clinical presentation, with a peri-
cardial effusion of .1 cm depth, and echo densities in
the effusion, conﬁrms the diagnosis.200 Temporary
haemodynamic stabilization can be obtained by pericar-
diocentesis, ﬂuids, and positive inotropes. The patient
should be immediately transferred to the operating
room without any further investigation. Free wall
rupture has been also described as a rare complication
of dobutamine stress echocardiography after AMI.201
12.1.2. Post-infarction ventricular septal rupture
(VSR). VSR occurs in 1–2% of patients with AMI. Recent
data suggest a lower incidence and an earlier presen-
tation in the ‘thrombolytic era’.173,174,202 VSR usually
occurs in the ﬁrst 1–5 days after MI. The ﬁrst sign of
VSR is a pansystolic murmur usually at the left lower
sternal border in a patient with acute deterioration
and signs of AHF/cardiogenic shock after an AMI (see
Figure 7A).
Echocardiography will conﬁrm the diagnosis, and allow
assessment of ventricular function, deﬁne the site of
the VSR, the size of the left-to-right shunt, and the
co-existence of mitral incompetence (Figure 7B ).
Class I recommendation, level of evidence C
PAC oximetry with O2 step-up will allow estimation of
the pulmonary-to-systemic blood ﬂow ratio (usually two
or more).
Class III recommendation, level of evidence C for PAC
for diagnosis if echocardiography is diagnostic
Class IIa recommendation, level of evidence C for PAC
for monitoring
Haemodynamically compromised patients should have
IABC, vasodilators, inotropes, and (if necessary) assisted
ventilation. Coronary angiography is usually performed
because it has been demonstrated in some small retro-
spective studies that concomitant revascularization may
improve late functional status and survival.173,175
Virtually all patients treated medically die. Surgery
should be performed soon after the diagnosis in most
Table 13 Cardiac disorders and AHF requiring surgical
treatment
Cardiogenic shock after AMI in patients with multi-vessel
ischaemic heart disease
Post-infarction ventricular septal defect
Free wall rupture
Acute decompensation of pre-existing heart valve disease
Prosthetic valve failure or thrombosis
Aortic aneurysm or aortic dissection rupture into the
pericardial sac
Acute mitral regurgitation from:
Ischaemic papillary muscle rupture
Ischaemic papillary muscle dysfunction
Myxomatous chordal rupture
Endocarditis
Trauma
Acute aortic regurgitation from:
Endocarditis
Aortic dissection
Closed chest trauma
Ruptured aneurysm of the sinus of Valsalva
Acute decompensation of chronic cardiomyopathy
requiring support by mechanical assist devices
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patients. Hospital mortality is 20–60% in patients under-
going surgical repair. Improvements in surgical technique
and myocardial protection improved outcome in recent
series.173,202
There is a developing consensus that surgery should be
performed as soon as the diagnosis is made, because the
rupture can abruptly expand resulting in cardiogenic
shock, the most important determinant of adverse
outcome.174,203 The patients with VSR should be operated
on urgently if they are in haemodynamically stable
condition and immediately if they are in cardiogenic
shock.
Class I recommendation, level of evidence C
Recently, left ventricular outﬂow tract (LVOT) obstruc-
tion with compensatory hyperkinesis of the basal seg-
ments of the heart has been described in some patients
with apical anterior myocardial infarction as a cause
of a new systolic murmur and cardiogenic shock. It
persists until appropriate therapy decreases the LVOT
obstruction.204
12.1.3. Acute mitral regurgitation. Acute severe MR is
found in 10% of patients with cardiogenic shock after
AMI.205 It occurs 1–14 days (usually 2–7 days) after the
infarction. In acute MR from complete papillary muscle
rupture most of the non-operated patients die in the
ﬁrst 24 h.
Partial rupture of one or more papillary muscle heads is
more common than complete rupture and has a better
survival. In most patients the acute MR is secondary to
papillary muscle dysfunction rather than to rupture.
Endocarditis may also be a cause for severe MR and
requires reparatory surgery.
Acute severe MR is manifested by pulmonary oedema
and/or cardiogenic shock. The characteristic apical
systolic murmur may be absent in patients with severe
MR, due to the abrupt and severe elevation of left
atrial pressure. Chest radiography shows pulmonary
congestion (this may be unilateral). Echocardiography
will establish the presence and severity of MR and
permit assessment of LV function. The left atrium is
usually small or slightly enlarged. In some patients
transoesophageal echocardiography may be needed to
establish the diagnosis.
A PAC can be used to exclude VSR; the PCWP tracing
may show large regurgitant V waves. Ventricular ﬁlling
pressures can be used to guide patient management
(Figure 7C ).
Class IIb recommendation, level of evidence C
Most patients need IABC for stabilization before cardiac
catheterization and angiography. When a patient devel-
ops acute MR, the operation should be done early
because many patients deteriorate suddenly or develop
other serious complications.206 The patient with acute
severe MR and pulmonary oedema or cardiogenic shock
requires emergency surgery.
Class I recommendation, level of evidence C
13. Mechanical assist devices and
heart transplantation
13.1. Indication
Temporary mechanical circulatory assistance may be
indicated in patients with AHF who are not responding
to conventional therapy and where there is the potential
for myocardial recovery, or as a bridge to heart trans-
plant or interventions that may result in signiﬁcant
recovery of the heart function (Figure 8 ).
Class IIb recommendation, level of evidence B
Improvement in the design and function of the devices
will increase the number of potential candidates for its
short and long-term use in the future.
13.1.1. Intra-aortic balloon counterpulsation (IABC).
Counter-pulsation has become a standard component of
treatment in patients with cardiogenic shock or severe
acute left heart failure that (i) does not respond rapidly
to ﬂuid administration, vasodilatation, and inotropic
support; (ii) is complicated by signiﬁcant MR or rupture
of the interventricular septum, to obtain haemodynamic
stabilization for deﬁnitive diagnostic studies or treat-
ment; or (iii) is accompanied by severe myocardial
ischaemia, in preparation for coronary angiography and
revascularization.
Synchronized IABC is performed by inﬂating and deﬂa-
ting a 30–50-mL balloon placed in the thoracic aorta
through the femoral artery. The inﬂation of the balloon
in diastole increases aortic diastolic pressure and coro-
nary ﬂow while the deﬂation during systole decreases
after-load and facilitates LV emptying. IABC may dramati-
cally improve haemodynamics but its use should be
restricted to patients whose underlying condition may
be corrected (by, for example, coronary revasculariza-
tion, valve replacement, or heart transplant) or may
recover spontaneously (e.g. myocardial stunning very
early after AMI or open heart surgery, myocarditis).207
IABC is contraindicated in patients with aortic dissection
or signiﬁcant aortic insufﬁciency. It should not be used in
patients with severe peripheral vascular disease, uncor-
rectable causes of heart failure, or multi-organ failure.
Class of recommendation I, level of evidence B
13.1.2. Ventricular assist devices. Ventricular assist
devices are mechanical pumps that partially replace
the mechanical work of the ventricle (Table 14). They
unload the ventricle, thereby decreasing myocardial
work, and pump blood into the arterial system increasing
peripheral and end-organ ﬂow.208–210 Some devices
include a system for extracorporeal oxygenation.211
New devices intended for the treatment of chronic
(rather than acute) failure restrict the progression of
ventricular dilatation. Recently, a number of devices
have been developed for acute, short-term mechanical
circulatory support in patients with acute or acutely
decompensated heart failure. Some devices require a
median sternotomy and complex surgery. Others simply
extract blood from the arterial system, pumping the
blood back again into the arterial or venous vascular
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system. In some patients the haemodynamic and clinical
improvement may be spectacular.
If recovery from AHF or transplantation is not possible
then the use of ventricular assist devices is unacceptable.
The treatment of patients with LV assist devices vs. con-
ventional treatment in a randomized clinical trial impro-
ved the prognosis of end-stage heart failure patients
compared with conventional care, but was expensive
and accompanied by frequent infections and thrombotic
complications.212 Experience is needed for the implan-
tation and service of the pump and these devices
should only be used within the framework of an
institutional programme. Table 14 summarizes the more
frequently used systems and the main indications.
Class IIa recommendation, level of evidence B
Thromboembolism, bleeding, and infection are the
most common complications associated with the use of
ventricular assist devices.208–210 Haemolysis and device
malfunction are also frequent.
13.2. Heart transplantation
Transplantation can be considered as a possibility in
severe AHF known to have a poor outcome. This is the
Figure 8 Selection of candidates for LV assist devices. (a): No response to conventional treatment of AHF, including appropriate use of diuretics and
ﬂuids, intravenous inotropics and vasodilators. (b): End organ dysfunction, including severe systemic disease, severe renal failure pulmonary disease
or hepatic dysfunction, permanent central nervous injury. (c): Potential recovery of myocardial function or cardiac function, e.g. acute myocardial
ischaemia, post-cardiotomy shock, acute myocarditis, acute valvular heart disease, or candidate to heart transplant. (d): Absence of clinical improve-
ment after intra-aortic balloon pumping and mechanical ventilation. (e): Final indication may depend upon availability of device and experience of car-
diovascular team.
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case in severe acute myocarditis or in post-puerperal
cardiomyopathy or in a patient with major myocardial
infarction with an initially poor outcome after revascu-
larization. However, transplantation is not possible until
the patient’s condition has been stabilized with the aid
of devices and artiﬁcial pumps.
14. Summary comments
The clinical syndrome of AHF may present as de novo AHF
or as decompensated CHF with forward, left (backward),
or right (backward) dominance in the clinical syndrome.
A patient with AHF requires immediate diagnostic
evaluation and care, and frequent resuscitative measures
to improve symptoms and survival.
Initial diagnostic assessment should include clinical
examination supported by the patient’s history, ECG,
chest X-ray, plasma BNP/NT-proBNP, and other laboratory
tests. Echocardiography should be performed in all
patients as soon as possible (unless recently done and
the result is available).
The initial clinical assessment should include evalua-
tion of pre-load, after-load, and the presence of mitral
regurgitation (MR) and other complicating disorders
(including valvular complications, arrhythmia, and con-
comitant co-morbidities such as infection, diabetes mel-
litus, respiratory, or renal diseases). Acute coronary
syndromes are a frequent cause of AHF and coronary
angiography is often required.
Following initial assessment, an intravenous line should
be inserted, and physical signs, ECG and SPO2 should be
monitored. An arterial line should be inserted when
needed.
The initial treatment of AHF consists of:
. Oxygenation with face-mask or by CPAP (SPO2 target of
94–96%)
. Vasodilatation by nitrate or nitroprusside
. Diuretic therapy by furosemide or other loop diuretic
(initially intravenous bolus followed by continuous
intravenous infusion, when needed)
. Morphine for relief of physical and psychological dis-
tress and to improve haemodynamics
. Intravenous ﬂuids should be given if the clinical con-
dition is pre-load-dependent and there are signs of
low ﬁlling pressure. This may require testing the
response to an aliquot of ﬂuid.
. Other complicating metabolic and organ-speciﬁc con-
ditions should be treated on their own merits.
. Patients with acute coronary syndrome or other com-
plicated cardiac disorders should undergo cardiac
catheterization and angiography, with a view to inva-
sive intervention including surgery.
. Appropriate medical treatment by b-blocking agents
and other medical therapy should be initiated as
described in this report.
Further speciﬁc therapies (Figures 5, 6, 7 and Table 14)
should be administered based on the clinical and haemo-
dynamic characteristics of the patient who does not
respond to initial treatment. This may include the use
of inotropic agents or a calcium sensitizer for severe
decompensated heart failure, or inotropic agents for car-
diogenic shock.
The aim of therapy of AHF is to correct hypoxia and
increase cardiac output, renal perfusion, sodium excre-
tion, and urine output. Other therapies may be required
e.g. intravenous aminophylline or b2-agonist for bronch-
odilation. Ultraﬁltration or dialysis may be prescribed
for refractory heart failure.
Patients with refractory AHF or end-stage heart failure
should be considered for further support, where indi-
cated (Figures 7 and 8 ) including: intra-aortic balloon
pump, artiﬁcial mechanical ventilation, or circulatory
assist devices as a temporary measure, or as a ‘bridge’
to heart transplantation.
Table 14 Mechanical assist devices
Device System Main indication Comments
Extracorporeal
Continuous ﬂow pumps Several Short term support Easiest to use. Cheapest
Centrifugal pumps Several Extensive experience
May include extracorporeal membrane
oxygenators
Need for continuous monitoring
Patient bedridden
Pulsatile Thoratec Short term support Easy to use. Not expensive
Abiomed Post cardiotomy Need for continuous monitoring
LV and RV dysfunction Patient bedridden
Bridge to heart transplant
Intracorporeal
Implantable, pulsatiles Heart Mate Long term use possible Expensive
Novacor Bridge to transplant Patient may move and rehabilitate
Bridge to recovery
Total artiﬁcial heart No recovery expected Experimental
No transplant candidate Limited experience
Alternative to transplant
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The patient with AHF may recover extremely well,
depending on the aetiology and the underlying pathophy-
siology. Prolonged treatment on the ward and expert care
are required. This is best delivered by a specialist heart
failure team that can rapidly initiate medical manage-
ment and attend to the information needs of the
patient and family.
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